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ABSTRACT
Inflammatory breast cancer (IBC) is the most insidious form of locally advanced disease.
Although rare and less than 2% of all breast cancer, IBC is responsible for up to 10% of
all breast cancer deaths. Despite the name, very little is known about the role of
inflammation or immune mediators in IBC. Therefore, we analyzed blood samples from
IBC patients and non-IBC patients, as well as healthy donor controls to establish an IBCspecific profile of peripheral blood leukocyte phenotype and function of T cells and
dendritic cells and serum inflammatory cytokines.

Emerging evidence suggests that host factors in the microenviromement may interact
with underlying IBC genetics to promote the aggressive nature of the tumor. An integral
part of the metastatic process involves epithelial to mesenchymal transition (EMT) where
primary breast cancer cells gain motility and stem cell-like features that allow distant
seeding. Interestingly, the IBC consortium microarray data found no clear evidence for
EMT in IBC tumor tissues. It is becoming increasingly evident that inflammatory factors
can induce EMT. However, it is unknown if EMT-inducing soluble factors secreted by
activated immune cells in the IBC microenvironment canπ account for the absence of
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EMT in studies of the tumor cells themselves. We hypothesized that soluble factors
from immune cells are capable of inducing EMT in IBC.

We tested the ability of immune conditioned media to induce EMT in IBC cells. We
found that soluble factors from activated immune cells are able to induce the expression
of EMT-related factors in IBC cells along with increased migration and invasion.
Specifically, the pro-inflammatory cytokines TNF-α, IL-6 and TGF-β were able to
induce EMT and blocking these factors in conditioned media abated the induction of
EMT. Surprisingly, unique to IBC cells, this process was related to increased levels of Ecadherin expression and adhesion, reminiscent of the characteristic tightly packed tumor
emboli seen in IBC samples.

This data offers insight into the unique pathology of IBC by suggesting that tumor
immune interactions in the tumor microenvironment contribute to the aggressive nature
of IBC implying that immune induced inflammation can be a novel therapeutic target.
Specifically, we showed that soluble factors secreted by activated immune cells are
capable of inducing EMT in IBC cells and may mediate the persistent E-cadherin
expression observed in IBC. This data suggests that immune mediated inflammation may
contribute to the highly aggressive nature of IBC and represents a potential therapeutic
target that warrants further investigation.
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Chapter 1: Introduction
Inflammatory Breast Cancer

1

THE DISEASE
Breast cancer claims the lives of more than 39,000 women in the United States
every year and is the leading cause of death among American women aged 45-55. Over
232,000 women in the United States are diagnosed with breast cancer every year and for
most women, cancers confined to the breast are highly survivable. As with most cancers,
breast cancer mortality results from metastatic disease. Inflammatory breast cancer (IBC)
is the most insidious form of locally advanced breast cancer and while defined as a local
entity, it rapidly progresses to metastasis and has a very poor prognosis. However, the
role of inflammation in inflammatory breast cancer is poorly understood.
IBC was first described in 1814 by Sir Charles Bell as “a purple color on
the skin over the tumor accompanied by shooting pain” (1) although pain is infrequently
associated with disease progression (2). Lee and Tannenbaum first published the term
“inflammatory carcinoma of the breast” in 1924 (3). The first diagnostic criteria for IBC
were published by Haagensem in 1956 (4). A similar disease, “rapidly progressing breast
cancer” (poussée évolutive) has been described, particularly in Tunisia and northern
Africa, and has formed the basis of much of the etiological studies of IBC (5).
Unfortunately, recent reviews suggest that these cases may not be true IBC and therefore
our understanding of IBC is limited.
IBC usually affects women 50-55 years old.

This demographic is slightly

younger than patients with non-IBC. In contrast to IBC, lactation associated mastitis, a
common differential diagnosis, tends to afflict women of a slightly younger age.
Common findings on mammography are skin thickening, diffusely increased breast
density, and trabecular thickening but are often reported as negative contributing to
delayed diagnosis (2).
2

The histologic hallmark of IBC is dermal lymphatic invasion (DLI) of tumor
emboli that retract away from the endothelial lining (6). However, pathologic evidence
of dermal lymphatic involvement is not required for diagnosis as negative results may be
due to sampling errors. Additionally, lymphatic tumor emboli may be observed in nonHodgkin’s lymphoma (7) and non-inflammatory breast cancer (8). It is important to note
that inflammatory breast cancer is primarily a clinical diagnosis according to the
American Joint Committee on Cancer (AJCC) staging manual (9).
IBC is a separate entity from other non-inflammatory locally advanced breast
cancers (LABC). According to the Surveillance, Epidemiology and End Results (SEER)
Program database, IBC median survival is 2.9 years vs. 6.4 years for LABC (10).
Suggesting a unique genetic background, blacks have at least 50% higher incidence than
whites and are diagnosed at an earlier age (11). In contrast to non-IBC, women with
aggressive breast cancer are more likely to have had a younger age of first parity (11). A
high body mass index (BMI) is associated with IBC in both premenopausal and
postmenopausal women. Interestingly, BMI is only associated with increased non-IBC
breast cancer only in pre-menopausal women (11).
Three types of IBC are recognized: primary, secondary and occult (12). Primary
IBC arises as a new malignant tumor. In contrast, inflammation that develops later in the
course of cancer progression is referred to as secondary IBC. Occult was first defined by
Salzstein in 4 patients (13).

IBC is not limited to any specific histologic type.

Pathologists usually report a poorly a differentiated ductal carcinoma, but IBC also can
be lobular, medullary, colloid carcinoma or comedo-type ductal carcinoma in situ
(DCIS). Notably, locally advanced breast cancer, which also involves dermal penetration
but lacks dermal lymphatic involvement of IBC, is very often medullary or medullarylike (12).
3

According to the SEER database, IBC presents with more ER negative disease
than non-IBC and is frequently Her2 amplified or mutated (10). In addition to the typical
breast cancer prognostic markers, several other pathways have been implicated in IBC
including E-cadherin, Muc1, and RhoC (14) and p53 is frequently mutated (15).
E-cadherin is a calcium dependent transmembrane glycoprotein that mediates
homotypic adhesion between epithelial cells (16). Loss of E-cadherin expression is
associated with the epithelial to mesenchymal transition (17) and is generally a poor
prognostic factor in breast caner (18).

In IBC, however, E-cadherin expression is

maintained (19) and is up-regulated in IBC models (20). The clusters of tumor cells that
comprise the lymphatic emboli characteristic of IBC are maintained through E-cadherin
interactions. Sanford Barsky’s lab showed that anti-E-cadherin would cause dissolution
of tumor emboli in the Mary-X IBC mouse model (20). Therefore, E-cadherin is thought
to be a unique factor in IBC.
STEM CELLS

The Marry-X model exhibits “florid lymphovascular invasion” (21) and expresses
stem cell-like phenotypes in culture including stellar, rex-1, nestin, H19, oct-4, nanog,
sox-2, CD44+CD24-/low, ALDH1, and CD133 but not CD34 (22). Notably, the authors
claim that non-IBC breast cancer cells lines do not express CD133.
Aldehyde dehydrogenase (ALDH) activity is involved in the metabolism of
retinoic acid which signals through the retinoic acid receptor to maintain cells in a stem
cell-like undifferentiated state (23).

ALDH activity may contribute to the therapy

resistant properties (24) of stem cells. Furthermore, ALDH1 expression has recently
been shown to be a poor prognostic factor in breast cancer (25). In this paper, the authors
describe a fluorescence-based technology that allows easy identification of the aldehyde
4

expressing cells by a bright fluorescence of the proprietary agent Aldefluor (ALDHbr).
Although ALDH1 is typically thought to be the most influential isoform of ALDH in
stem cell maintenance, Charafe-Jauffret et al note that different isoforms of ALDH1
contribute to the ALDHbr population (26). In IBC, aldehyde and alcohol metabolism
pathways were found to be upregulated in IBC vs. non-IBC in a pathway analysis of
Affimetrix chip data from tumor epithelium laser capture microdissection (27).
Therefore stem cell signaling through ALDH may play a critical role in the biology of
IBC.
INFLAMMATION IN IBC
There is much debate over whether the inflammatory features observed in
inflammatory breast cancer represent a true inflammatory process.

Inflammation is

traditionally defined by the Latin rubric: calor, dolor, rubor and tumor, meaning “heat,
pain, redness, and swelling.” Each of these is normally attributed to the action of local
inflammatory cytokines released in response to a pathologic process (28). However, in
IBC, current consensus contends that inflammation is caused by a continuous growth of
tumor cells within the lymphatic (and occasionally venous) vessels that eventually blocks
all drainage from the tissue resulting in the edema. Inflammatory cellular infiltrates are
limited to lymphocytes and monocytes invading the perivascular area in response to the
lymphatic blockage. Other leukocytes such as neutrophils, eosinophil and mast cells are
not commonly seen in IBC (12). While these leukocytes are seen around the periphery,
inflammatory cells are rarely reported in the tumor field (29). Most of the reviews of
leukocytic infiltrates in IBC are anecdotal and a clear consensus is hard to establish.
Unfortunately, although a thorough review of leukocytic infiltrates in IBC has not been
published, it is beyond the scope of the current study.
5

As IBC presents with inflammatory features in the breast, it can be easily
confused with mastitis, an acute inflammation of the breast that is almost exclusively
associated with lactation.

The skin overlying a mastitis-related abscess is typically

smooth and shiny whereas IBC presents with the characteristic peau d’orange or orangepeel skin. Mastitis related inflammation quickly resolves or progresses to abscess and
can be readily treated with antibiotics (12).
As secretion of cytokines is one of the defining hallmarks of inflammation,
several studies have examined cytokines in model systems and patient material. Stephen
Ethier’s group in Michigan developed the SUM149 cell line from an aggressive
inflammatory breast cancer (30) and showed that it produces IL-1α and IL-1β in response
to autocrine amphiregulin stimulation of epidermal growth factor receptor (EGFR) (31).
However, Sofia Merajver’s group from the same instuition has unpublished data
suggesting that IBC tumors produce “negligible levels” of IL-1 (8). Similarly, Bièche et
al found similar expression levels of inflammatory cytokine mRNA in IBC and LABC
(32). In this study, Bièche et al performed RT-PCR analysis of 538 genes in 36 IBC and
22 LABC samples collected over 7 years from one institution in France and found similar
levels of interleukin (IL)-1α, IL-1β, IL-6, IL-8, IL-10, interferon (IFN)-γ, and tumor
necrosis factor (TNF)-α. However, IL-6 expression was 9.3 times higher in IBC than
LABC. Additionally, they reported increased expression of Cox-2. It is worth noting
that this was a small study and although ER was found to be less frequently expressed in
IBC, as expected, they study did not find expression differences in the other pathways
most frequently associated with IBC including E-cadherin, Ras homolog gene family,
member C GTPase (RhoC) or WNT1-inducible-signaling pathway protein 3 (Wisp3, as
known as CCN6). Further reverse transcription-polymerase chain reaction (RT-PCR)
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analysis of the same sample set found that 35 of 60 (58%) NF-κB pathway related genes
were up-regulated in IBC (33).
The transcription factor NF-κB is a critical in regulator of inflammation. The IL1 receptor is highly homologous to the NF-κB inducing Toll-like receptors (TLR) that are
conserved from drosophila to humans (34) and there is a positive feedback loop between
IL-1 and NF-κB activation where each induces activation of the other. Gene chip studies
at MD Anderson have shown that expression of IL-1β mRNA is significantly higher in
IBC cell lines than in non-IBC MCF-7. Additional NF-κB dependent genes such as
CXCL1 were also unregulated in IBC. The inflammatory intermediary Cox-2 is highly
expressed in the IBC cell line SUM149 relative to non-IBC cell lines (35).
Although the clinical indications of inflammation in IBC seem to be primarily
related to blockage of dermal lymphatic vessels, this research has shown that sub-cellular
inflammatory signaling including Cox-2 and NF-κB is highly prevalent in the SUM149
model cell line.
MODEL SYSTEMS
Inflammatory Breast Cancer is defined by its clinical and pathological
presentation, there is no current molecular determinant. As such model systems are a bit
limited in their ability to fully recapitulate the disease. A limited number of cell lines
derived from patients with confirmed IBC are available and these serve as the basis for
most in vitro work. Stephen Ethier’s group in Michigan developed the SUM149PT and
SUM190PT cell lines from the primary tumors of patients diagnosed with aggressive
inflammatory breast cancer (30).

The SUM190 cell line harbors a chromosomal

amplification of the Her2/neu oncogene whereas the SUM149 is triple receptor negative
and lacks expression of the three primary breast cancer prognostic markers: ER,
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progesterone receptor (PR) and the epithelial growth factor receptor family member
Her2. Such triple receptor negative breast cancers (TNBC) (sometimes referred to as
basal-like) are often highly aggressive and it can be difficult to know if SUM149 is
modeling IBC behavior or TNBC behavior. Several additional Her2+ IBC cell lines exist
including KPL4 and a cell line recently developed at MD Anderson, IBC-3(36). The
MARYX model is a human IBC cell line that is passaged through murine xenografts.
The model recapitulates the tumor emboli so common in IBC, however the cell line is not
readily available. van Golen’s group has been describing an in vitro a model that can
mimic the oscillating interstitial fluid pressure within the lymphatics (37).

IMMUNOLOGY
IMMUNOLOGY AND BREAST CANCER
Tumor Infiltrating Leukocytes
Most studies of tumor leukocytic infiltrates in breast cancer rely on single color
stains. Ruffell et al compared malignant breast tissue, non-adjacent normal breast tissue
and peripheral blood as a control using several multi-parameter techniques in a small
series of 20 breast cancer patients. They reported that activated T-cells constitute the
largest proportion of infiltrating leukocytes in the tumors of chemotherapy naïve patients.
In these samples, macrophages are rare in the tumor but more common in the nonadjacent normal tissue. In contrast, myeloid cells are more common in the malignant
tissue of patients, post-chemotherapy (38).
IMMUNOLOGY AND IBC
Immunological studies of inflammatory breast cancer are limited. After anecdotal
reports of immune suppression in French breast cancer patients diagnosed with poussée
8

évolutive (PEV) or rapidly progressing breast cancer, Levin et al. used delayed
hypersensitivity skin tests (5) and in vitro cellular immunity tests (39) to study immunity
in PEV patients in Tunisia. In both studies, the authors found almost no difference
between PEV+ and PEV- patients with respect to tumor antigen, recall antigen, and
mitogen (phytohemaglutinin A or Concanavalin A) stimulation.

Unfortunately,

diagnostic criteria used in these studies were not based on the current definition of IBC,
making interpretation of these data difficult (40).
About the same time, immunotherapy trials using Bacillus Calmette-Guerin
(BCG) as an adjuvant were conducted in breast cancer patients (41). A long-term followup of IBC patients vaccinated with allogeneic tumor + BCG found 4 of 13 patients (31%)
were still alive after 10 years (42).

Interestingly, Pogo et al. have reported that

components of a human virus very similar to mouse mammary tumor virus (MMTV) are
present in IBC patients (43). This is highly intriguing for a number of reasons including
1) MMTV is a well known mammary oncogene that is frequently used as a model for
breast cancer in mice and 2) it suggests an immune aspect to IBC. Unfortunately, the
MMTV data are yet to be confirmed. Additionally, there is a single case report from
1994 that notes a reconstitution of immune parameters following administration of
subcutaneous IL-2 (44). Recent anecdotal evidence suggested that there is a high
prevalence of viral infection in IBC. Overall the literature is very thin and a basic
understanding of immune competence in IBC is needed.
MOLECULAR SIGNALING

Recent research has suggested that several signaling pathways contribute to the
unique aggressive nature of inflammatory breast cancer. Similar to other breast tumors,
p53 and Her2 are frequently mutated in IBC (45). More unique to IBC is an increased
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expression of the oncogene RhoC GTPase, the cell adhesion molecules E-cadherin and
MUC-1 and loss of the tumor suppressor Wnt-1 induced secreted protein 3 (WISP-3, also
known as “lost in IBC”) (46, 47). Furthermore, IBC tends to be highly vascularized (47)
with higher levels of vascular endothelial growth factor (VEGF) than non-inflammatory
breast cancer (48).
The tumor suppressor p53 is often called the “guardian of the genome” due to its
ability to prevent replication of damaged DNA (49).

Moll et al. found that p53

dysfunction in IBC occurs by two major mechanisms. The authors found that in p53
positive samples with nuclear localization, the protein was impaired by a variety of
missense mutations. In contrast, wild type p53 was found in IBC patients who were p53
negative or with cyoplasmically localized tumors. Therefore, the authors proposed that
missense mutation and nuclear exclusion are the primary mechanisms of p53 alteration
IBC (50).
Over-expression of E-cadherin is an interesting phenomenon in IBC. E cadherin
helps anchor epithelial cells together. In epithelial cancers, E-cadherin is typically lost in
malignant progression as its down-regulation is associated with the epithelial to
mesenchymal transition and therefore invasion and metastasis. In contrast, E-cadherin is
highly expressed in the lymphovascular emboli of IBC. β-catenin acts as an adapter
protein binding E-cadherin to the actin cytoskeleton (20). This association of E-cadherin
with β-catenin should sequester β-catenin in the cytoplasm and limit Wnt signaling.
Similarly, WISP3 is typically lost in IBC (51). Interestingly, WISP3, or cystein-rich
protein CCN6, seems to maintain cell adhesion and E-cadherin expression. Loss of
CCN6 in non-IBC cells lead to a down-regulation of E-cadherin through induction of
Snail and Zinc finger E-box-binding homeobox 1 (ZEB1) (52) which concurs with the
increased expression of Snail in IBC (32).
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Although IBC tumor cells clump together due to homotypic interactions of Ecadherin, the characteristic emboli retract from the endothelial wall. Sanford Barsky’s
lab (53) showed that although the adhesion molecule MUC1 is overexpressed in the
MARY-X model, sialyl-Lewisx/a carbohydrates are markedly decreased due to a loss of
α3/4-fucosyltransferase activity. Without the sialyl-Lewisx/a moieties, MUC1 and other
adhesion molecules are unable to bind the E-selectin on the endothelial vessels (53).
RhoC GTPase is typically overexpressed in IBC (46). RhoC is a member of the
ras with high homology to RhoA. The ras signaling pathway initiates cell motility and
focal adhesions (14). As prenylation is required for ras function, a farnesyl transferase
inhibitor may be useful in treating IBC (54).
SUMMARY

In conclusion, inflammatory breast cancer is a rare but highly aggressive form of
breast cancer. A number of clinical, pathological, and molecular attributes make IBC a
distinct entity from other locally advanced breast cancers. The disease is characterized
clinically by erythema and edema of the breast and a rapid disease progression. Although
not required for diagnosis, the pathological hallmark of IBC is the presence of tumor
nests in the dermal lymphatics.

These emboli are held together by E-cadherin as

confirmed by the MARY-X mouse xenograft model. Additionally, IBC is typically ERwith altered Her2. RhoC GTPase is typically over-expressed and WISP3 is consistently
lost. Although IBC is not a true inflammatory process with few infiltrating leukocytes
and minimal production of inflammatory cytokines, the tumor is characterized by and
high levels of angiogenic signaling and expression of the Cox2 and NF-κB inflammatory
signaling pathways.
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A diagnosis of inflammatory breast cancer has been associated with all intrinsic subtypes
of breast cancer in frequencies fairly similar to breast cancer in general. Furthermore, no
specific molecular event has been identified as a causative agent of IBC. As such, it is
possible that the factors that make IBC such an aggressive disease may not be intrinsic to
the tumor. We propose that host factors from the tumor microenvironment may play a
pivotal role in tumor evolution. As IBC is defined by the presence of inflammatory
features, later chapters of this thesis will examine the relationship between inflammatory
factors and IBC.
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RESEARCH OBJECTIVES
The overall goal of this project is to understand the role of immune system and immune
mediated inflammation in inflammatory breast cancer. The central hypothesis is:

Inflammatory breast cancer (IBC) is distinguished from non-IBC
by unique immunological characteristics that contribute to the
rapid progression of the disease.

To that end, four specific aims are offered:

Specific Aim 1: Establish that IBC patients have a serum cytokine profile that is unique
from that of non-IBC and healthy donors
Specific Aim 2: Establish IBC patients have a hematologic profile that is different from
that of non-IBC and healthy donors
Specific Aim 3: Establish that the peripheral blood cells of IBC patients have functional
changes that are unique and distinguishable from those of non-IBC and healthy donors
Specific Aim 4: To establish that immune mediated inflammation induces aggressive
changes in inflammatory breast cancer tumor cells
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Chapter 2: Soluble Factors
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POPULATION STUDIED

In order to establish a serum cytokine profile in inflammatory breast cancer, we
analyzed peripheral blood samples obtained under several University of Texas MD
Anderson Cancer Center IRB approved protocols including Lab08-0199 “Reactivation of
Epstein Barr virus in patients with breast cancer” and 2006-1072 “Inflammatory Breast
Cancer Registry.” Lab08-0199 served as the basis for the remainder of the studies in this
dissertation and is described in the following chapter. The Inflammatory Breast Cancer
Registry protocol 2006-1072 was initially set up to capture all newly diagnosed IBC
patients with (M1) or without (M0) de novo metastases at The University of Texas MD
Anderson Cancer Center.

The protocol was later expanded to include Cohort II

consisting of IBC patients who had received systemic therapy. For serum cytokine
profiling 125 treatment-naïve and 57 previously treated IBC patients were analyzed.
Under protocol Lab08-0199, samples were collected at the start of a new line of therapy.
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Table 2. 1
Patient characteristics for serum cytokine studies. Patients in this study were
recruited under MD Anderson IRB-approved protocols Lab08-0199 and 2006-1072.
Patients included locally advanced breast cancer patients with and without inflammatory
features (IBC and LABC) and Stage IV metastatic patients with and without
inflammatory features (MIBC and MBC). Tumor subtypes are derived from pathological
report, TNBC tumors lacked expression of ER, PR and Her2; tumors were classified as
Her2+ if they were IHC 3+ or FISH+; tumors were classified as luminal if they were
positive for hormone receptors (ER and/or PR) staining but not Her2 amplified.
Abbreviations: HR, Hormone receptor positive IBC Inflammatory Breast Cancer; LABC,
Locally Advanced Breast Cancer; MBC, Metastatic Breast Cancer; MIBC, Metastatic
breast cancer with inflammatory features; TNBC, triple receptor negative breast cancer.
Healthy donors (HD) consisted of women without cancer and of age 24-60 recruited from
MD Anderson Cancer Center.
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N
Age

Race

Stage
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Grade
Treatment Status
Subtype
Lymphatic Invasion

Asian/Pacific Islander
African American
Spanish, Hispanic
Caucasian
II
III
IV
1
2
3
Treatment Naive
Previously Treated
HR+
Her2 amplified
TNBC
No
Yes

IBC

LABC

MBC

MIBC

HD

106
52.2
(23 – 80)
2
10
11
83
106
1
25
68
79
27
33
48
24
24

30
51.6
(32 - 67)
1
3
6
20
14
16
0
3
8
19
29
1
15
9
6
16

28
53.3
(34 – 76)
1
3
5
19
28
0
8
14
6
22
13
8
7
5

76
51.7
(25 – 78)
0
7
5
64
76
1
17
51
46
30
25
25
26
14

29
39.4
(24 – 60)

44

7

10
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BACKGROUND
To establish a profile of systemic soluble inflammatory factors in inflammatory
breast cancer, serum samples were analyzed in batch using Luminex multiplex bead
technology. The Luminex cytokine assays are similar to a sandwich enzyme-linked
immunosorbent assay (ELISA) consisting of an immobilized capture antibody and a
reporter-conjugated detection antibody. In an ELISA the capture antibody is bound to a
polystyrene plate; samples, standards and in some cases, analytes, are indexed to the
physical location in the plate. Luminex assays conjugate the capture antibody to a
polystyrene bead filled with a precise ratio of flourophores that give the bead a unique
fluorescent signal that can be decoded by two fluorescent parameters on a flow cytometer
(55). Different detection antibodies are conjugated to different colored beads and added
to each sample in multiplex. The first generation Luminex technology allows up to 100
different beads to be read, but in practice, antibody interactions become problematic
above multiplexes with 30 to 40 analytes.
In this study, 45 different factors were analyzed in 5 separate panels.

The

cytokines are listed in Table 2. 2, with a brief description of each. Cytokines and
chemokines can be highly promiscuous, as most are derived from multiple sources and
act on a variety of targets. The chemokines in particular (listed on the second page of
Table 2. 2) can bind to multiple receptors.

Furthmore, many of the inflammatory

pathways are highly redundant with small functional differences between molecules. As
such, an inflammatory profile can be different in different patients. Therefore, as a first
pass, we looked at the sum of the profile (literally): the z-scores each for cytokine were
summed to give an unbiased, equal weight to each factor amalgamated into a single
number. For this total expression profile, there was no difference between IBC and non19

IBC (p = 0.171). However, IBC, MIBC and LABC had lower total expression of
cytokines than HD (p < 0.001, p = 0.003, and p = 0.001) but MBC was not significantly
different from HD (p = 0.055). This did not seem to be treatment related as the same
relationships held when looking only at treatment naïve patients (p = 0.001, p = 0.008
and p = 0.003 with MBC vs. HD p = 0.191). It is possible that this is due to lower total
protein levels, which might be possible to correct for using total serum albumin, but this
was not analyzed.
Systemic inflammation can be estimated by looking at levels of C-reactive protein
(CRP) that binds phosphocholine on the surface of damaged cells and some microbes to
activate complement. In contrast to the other factors profiled here, CRP is produced
almost exclusively by the liver in response to other inflammatory factors such as IL-6.
Normal CRP levels are below 10 mg/L. Following an acute assault, CRP serum levels
rises within 2 hours and can peak at around 200 mg/L within 2 days during an active
bacterial infection. Mild inflammation, viral infections and late pregnancy generally
have CRP levels between 10-40 mg/L. Chronically elevated levels have been associated
with inflammatory conditions such as arthritis and with malignancies. Even levels in the
high range of normal have been associated with an increased risk of cardiovascular
disease. Interestingly, statins, which are currently of great interest for their possible
protective effects in breast cancer (56), have been shown to reduce CRP levels (57).
Cytokines perform several basic functions. Table 2. 2 groups cytokines by the
most common function for each cytokine. There are inflammatory factors, angiogenic
factors, factors that support a type I cellular immune response, factors that drive a type II
humoral response, anti-inflammatory factors, growth factors, hematopoietic growth
factors, chemokines that act through G-protein coupled receptors that give directional
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signals, and factors that are highly associated with bone metabolism (critical in breast
cancer as bone is one of the most frequent metastatic sites).
These are general categories and most factors will fall into several different
categories, and even show diametrically opposed functions under different conditions.
For example, IL-6 is sometimes considered anti-inflammatory because it opposes the type
I immune response which is usually initiated through cells expressing both the IL-6
receptor (IL-6R) glycoprotein 130 (GP130). While GP130 is ubiquitously expressed, IL6R has a limited expression pattern. However, soluble forms of the IL-6R are able to
interact with both soluble IL-6 and membrane-bound GP130 to initiate signaling in a
wide variety of cells. This signaling complex initiates signal transducer and activator of
transcription 3 (Stat3) (58). This dual role of IL-6 may indicate that IL-6 plays a key role
in the transition from innate to adaptive immunity. Early stages of a typical acute
immune response include the recruitment of neutrophils and then replaced by monocytes
and T cells after 1 or 2 days. This early stage includes inflammatory factors TNF-α and
IL-1β that activate neutrophils.

Proteolytic cleavage of the IL-6R by the invading

neutrophils can release sIL-6R to initiate trans-signaling and induce the switch away from
neutrophil-attracting chmokines like (Groα, IL-8 and fractlakine) to monocyte-attracting
chemokines (MCP-1, and MCP-2) (59, 60). IL-6 trans-signaling also recruits T-cells
(61). Critically, IL-6 signaling also induces EMT and stem-like properties in breast
cancer cells (62) Trastuzumab-induced cancer stem cell expansion with a concomitant
increase in Twist or Vimentin and loss of EpCAM and E-cadherin is mediated by IL-6
(63). Such inflammatory signals can derive from the tumor, invading mesenchymal
stromal cells (64), or hematopoietic cells. In addition to IL-6, IL-8 has also been shown
to be critical in maintaining breast cells in a stem-like state (65, 66). As such, IL-6 and
IL-8 levels can be critical regulators of metastatic potential in breast cancer.
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As mentioned above, TNF-α and IL-1β are critical factors in acute inflammation.
These two cytokines are potent inducers of nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB), one of primary inflammatory signaling pathways and a critical
promoter of inflammation associated cancers (67). TNF-α activates NF-κB through
IκBβ (68). Receptor activator of nuclear factor kappa-B ligand (RANKL), critical in
bone metabolism through the activation of osteoclasts (69), is also critical in during
mammary gland development (70) and tumorigenesis (71). During pregnancy, RANKL
activates NF-κB through IκBα (70) to promote cyclin D1 dependent proliferation of
epithelial cells. As such, dysregulated inflammatory signaling through NF-κB can drive
proliferative cells.
In addition to NF-κB, cyclin D1 proliferation also requires AP1 signaling, often
derived from growth factors such as epidermal growth factor receptors EGFR and Erbb2
(72). Epidermal growth factor (EGF) and Transforming growth factor alpha (TGF-α) are
stong inducers of EGFR signaling. EGF is particularly important in TNBC (73) (Ueno
and IBC (74).
The adaptive immune response has been divided into 2 broad classes: a type-I
response driven by cytotoxic T-cells and a humoral type-II response driven by B-cells.
CD4+ helper T cells (TH) produce cytokines that polarize these dichotomous responses.
The type-I (cellular) response is typified by a class of cytokines, such as interferon
gamma (IFN-γ), interleukin-2 (IL-2), and IL-12. These induce and are produced by type1 polarized T-cells referred to as TH1. In contrast, the type-II (humoral) response favors
the production of IL-4, IL-5, and IL-13. These are referred to as TH2 cytokines. As IL10 and IL-6 promote B cell growth, these are typically considered TH2 cytokines, as
well. As the TH2 cytokines inhibit the production of TH1 cytokines, they are sometimes
considered anti-inflammatory. But more importantly, the TH1 response is generally
22

considered to control tumor growth through the activation of cytotoxic killing whereas
the TH2 polarization is considered to promote tumor immune evasion and tumor growth.
For example, TH2 polarized CD4+ cells have been shown to induce a type-II polarization
in tumor infiltrating macrophages that produce EGF to promote tumor growth(74).
Therefore, the level of expression of TH1 and TH2 cytokines can promote tumor control
by the immune system or tumor progression.
Recently, a third type of adaptive response has been identified that controls
extracellular bacteria, particularly at epithelia. Primed by IL-6, TGF-β, and IL-1β, the so
called TH17 response is typified by production of IL-17 family members.

This is

considered to be a highly inflammatory response and is related to auto-immunity. In this
study, we focused on the prototypical cytokine IL-17 and the IL-12p40 subunit that is
involved in IL-12 (TH1) polarization and IL-23 TH17 polarization.
TGF-β is usually considered an anti-inflammatory agent, yet with the induction of
TH17 is a very strong promoter of inflammation. In conjunction with IL-10, TGF-β
produced by regulatory T cells (TReg) is a potent inhibitor of both TH1 and TH2
responses.
These cytokines are summarized in the tables on the following pages.
INFLAMMATORY BREAST CANCER SERUM SIGNATURE
To see if an IBC-specific pattern of inflammation exists, we performed an
unsupervised hierarchical clustering of the 45 serum cytokines as seen in Figure 2. 1 on
page 27. No clear IBC-specific pattern could be discerned.
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Table 2. 2
List of cytokines analyzed. Forty-five cytokines were analyzed by Luminex multiplex
beads including inflammatory cytokines, angiogenesis-related factors, T-helper (TH)1-,
TH2-, and TH17-related cytokines, growth factors, hematopoietic growth factors,
chemokines and bone-related factors.
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Cytokine	
  

	
  

Name	
  

Function	
  

C-reactive protein
Interleukin 1 alpha
Interleukin 1 beta
Interleukin 1 receptor antagonist
Interleukin 6

Acute systemic inflammation, produced by liver
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Inflammatory
Inflammatory
Inflammatory
Inflammatory
Inflammatory

CRP
IL-1α
IL-1β
IL-1RA
IL-6

Inflammatory
Inflammatory
Inflammatory

sCD40L
TNF-α
TNF-β

CD154

Inflammatory

IL-8

CXCL8

Angiogenic
Angiogenic
TH1
TH1
Inflammatory

FGF-b
VEGF
IFN-γ
IL-2
IL-12P40

Basic fibroblast growth factor
Vascular endothelial growth factor
Interfern gamma (class II interferon)
Interleukin 2
Interleukin 12 p40 subunit (beta)

TH1
TH2
TH2
TH2
TH2
anti-viral
TH17
Antiinflammatory
Growth factor

IL-12P70
IL-13
IL-4
IL-5
IL-9
IFN-α2
IL-17
IL-10

Interleukin 12p70 (p40 + p35)
Interleukin 13
Interleukin 4
Interleukin 5
Interleukin 9
Interferon alpha 2
Interleukin 17
Interleukin 10

TGF-β

Transforming growth factor beta

Growth factor
Growth factor

EGF
TGF-α

Epidermal growth factor
Transforming growth factor alpha

Soluble CD40 ligand
Tumor necrosis factor alpha
Tumor necrosis factor beta
(lymphotoxin)
Interleukin 8

Expressed by mostly epithelial cells, important in maintaining epidermis
Pro-inflammatory, canonical inducer of NF-κB signaling
Prevents IL-1β signaling
Th2 and highly pro-inflammatory, increases with exercise, bone resorption, shown
to induce EMT
A TNF family member expressed on T cells that activates APC
Pro-inflammatory, induces IL-1 and IL-6
Functional homologue to TNF-α
Recruits neutrophils and granulocytes, angiogenic, supports breast cancer stem
cells
Promotes angiogenesis
Promotes angiogenesis
Primary TH1 cytokine, promotes macrophages and NK killing
T-cell growth factor, a TH1 cytokine, critical for TReg
Subunit sharted by IL-12 (promotes TH1, NK) and IL-23 (promotes TH17 and
inflammation)
Promotes TH1
Similar to IL-4, Promotes TH2, induces MMPs
The primary TH2 cytokine, induces TH2, humoral immunity
Produced by TH2 and mast cells
T-cell growth factor, TH2-like
Anti-viral
Primary TH17 cytokine, highly pro-inflammatory
Produced by monocytes, TH2, Treg; inhibits pro-inflammatory signaling, growth
factor for B cells
Highly pleiotropic, anti-inflammatory, anti-proliferative, strong inducer of
epithelial mesenchymal transition (EMT)
Promotes growth, differentiation, and proliferation
Similar to EGF, can bind EGFR

	
  

Cytokine	
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Hem. growth factor

Flt3L

Hem. growth factor

G-CSF

Hem. growth factor

GM-CSF

Hem. growth factor

IL-15

Hem. growth factor
Hem. growth factor
Hem. growth factor
Chemokine
Chemokine
Chemokine
Chemokine
Chemokine
Chemokine
Chemokine
Chemokine
Chemokine
Bone
Bone
Bone
Bone

IL-3
IL-7
sIL-2Rα
GRO
IP-10
MCP-1
MIP-1α
MIP-1β
MCP-3
Eotaxin
MDC
Fractalkine
OC
OPG
PTH
RANKL

	
  

Name	
  

Function	
  

Fms-related tyrosine kinase 3 ligand

Similar to stem cell factor, proliferation and differentiation of various blood cell
progenitors including dendritic cells
Stimulates proliferation and differentiation of granulocytes can also mobalize
stem cells from bone marrow
Stimulates proliferation and differentiation of granulocytes and monocytes

Granulocyte colony-stimulating factor
Granulocyte-macrophage colonystimulating factor
Interleukin 15

sCD25
CXCL1
CXCL10
CCL2
CCL3
CCL4
CCL7
CCL11
CCL22
CX3CL1

Interleukin 3
Interleukin 7
soluble IL-2 Receptor alpha (CD25)
Growth related oncogene
Interferon gamma-induced protein 10
Monocyte chemotactic protein-1
Macrophage inflammatory protein alpha
Macrophage inflammatory protein beta
Monocyte chemotactic protein-3
Eotaxin
Macrophage-derived chemokine
Fractalkine
Osteocalcin
Osteoprotegerin
Parathyroid hormone
Receptor activator of nuclear factor
kappa-B ligand

Similar to IL-2 promotes T and NK functions , usually trans-presented for
juxtacrine signaling
Growth factor for myeloid and lymphoid progenitors, matures pDC
Lymphocyte homeostasis
Shed from activated T and TReg, can inhibit IL-2 signaling
Neutrophil chemoattractant
Recruits hematopoetic cells
Recruits monocytes, dendritic cells and memory T cells
Activate granulocytes and induce inflammatory cytokines
Activate granulocytes and induce inflammatory cytokines
Similar to MCP-1, attracts monocytes
Binds CCR2, 3, 5, recruits eosinophils
Recruits mDC and IL-2 activated NK
Chemoattractant for T cells and monocytes
Promotes osteoblastic bone generation
Decoy for RANK-L
Bone resorption
TNF family member activated osteoclasts

Figure 2. 1
Unsupervised hierarchical clustering of serum cytokines shows no IBC signature.
45 Serum cytokines were measured using Luminex multiplex beads. Each cytokine was
normalized to the healthy donors using the formula (xj,i – µj,HD) / (SDj,HD) where µHD is the
mean of the healthy donors, SDHD is the standard deviation of the healthy donors for each
cytokine j and subjected to hierarchical clustering using the Person correlation as the
distance metric with average linkage clustering. Black values are near the mean of the
healthy donors, yellow represents measured serum concentrations higher than the mean
of the healthy donors and blue represents lower levels. The sample classification color
code is along the top: IBC, HD and non-IBC are shown in blue green and red,
respectively. No clear IBC-unique signature is observed. Note that the cluster of
upregualted inflammatory factors is not enriched for any subtype.
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We next looked at median levels each cytokine in IBC, non-IBC and healthy
donors. The data are summarized in heat-map form in Figure 2. 2 on page 31. In
contrast to our hypothesis, IBC is not characterized by increased inflammation. Using
CRP as a measure of general inflammation, median levels are slightly higher in IBC but
not significantly (p = 0.706). However, patients with metastatic disease, both MBC and
MIBC, have elevated levels of CRP compared to normal (p = 0.050 and 0.049,
respectively). MBC was higher than MIBC, but not significantly (p = 0.498). We might
expect inflammatory markers to increase with treatment as chemoradiation induces cell
death. In MIBC, the elevated CRP is not a result of treatment, as treatment naïve patients
have elevated levels of CRP as well (p = 0.032). In contrast, treatment naïve MBC
patients (n = 6) did not have elevated CRP levels (p = 0.965). In fact, with a median CRP
of 8.2 mg/L, MBC was only slightly higher than HD (median 5.6 mg/L) and with a trend
to be lower than MIBC (median = 24.9 mg/L, p = 0.097). While the number of treatment
naïve MBC patients is very small, this suggests there MIBC is a different entity than
MBC without inflammatory features.
Observing the median serum levels of the other inflammatory markers, the pattern
seems to hold: IBC is not characterized by systemic inflammation compared to LABC.
In contrast, osteoprotegerin (OPG), osteocalcin (OC), eotaxin, TGF-α, IFN-α, IL-3 and
IL-8 are all significantly lower in IBC than in LABC (p < 0.05).
Furthermore, looking at patients with metastatic disease, those with inflammatory
features (MIBC) had lower levels of inflammatory cytokines than those non-IBC
metastatic breast cancer including OPG, OC, eotaxin, G-CSF, FLT-3L, IFN-α, IL-17, IL7, IL-8, and MIP-1β (p < 0.05), although for most of these cytokines, treatment seemed
to contribute to the elevated levels as only OPG, OC and FMS-like tyrosine kinase 3
ligand (FLT3L) remained significant when looking at only treatment naïve patients.
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The TH1/TH2 balance (a sum of the HD standardized z-scores for IFN-γ, IL12p70 and IL-2 and subtracting IL-4, IL-5, IL-6, IL-10 and IL-13) seems to favor TH2 in
IBC and MIBC, again primarily in the treatment naïve patients.
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Figure 2. 2
Inflammatory breast cancer has lower inflammatory cytokines. The serum cytokine
data is presented as median values. As in the previous figure, low values are colored blue
and hi values are colored yellow. Note that the colors represent scaling, not significance.
All units are in pg/mL except CRP that is in mg/L. An expanded version of the figure is
on the following page. IBC = inflammatory breast cancer, LABC = locally advanced
breast cancer, MBC = metastatic breast cancer (without inflammatory features), MIBC =
metastatic breast cancer with inflammatory features, HD = healthy donors.
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IL-8 was significantly lower in IBC than in either LABC (p = 0.045) or HD (p =
0.03). Additionally, IL-8 was significantly lower in MIBC than in MBC (p = 0.027).
This is unexpected considering the important role IL-8 plays in maintaining breast cancer
stem cells (65, 66) and that IBC cell lines produce high levels of IL-8 as we have
previously shown (75). IL-8 has a serum half-life of about 10 minutes (76), so it seems
unlikely that tumor sequestration of IL-8 could explain the low levels observed in IBC.
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Figure 2. 3
IBC has low serum IL-8, but cell lines express high IL-8. IL-8 levels were measured
in sera of IBC, LABC, MBC and MIBC patients. IBC median IL-8 levels are
significantly lower than LABC (Mann-Whitney U p < 0.05). Likewise, median MIBC
serum IL-8 is significantly lower than MBC. When IL-8 production was measured in the
supernatants of breast cancer cell lines, the IBC cell lines expressed higher levels of IL-8
than non-IBC cell lines.
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The one cytokine that was significantly elevated in IBC was TGF-β1. In all
patients, there was a non significant increase in TGF-β1 in IBC compared to LABC (p =
0.139). However, when comparing only treatment naïve patients, IBC (median TGF-β1
34.0 mg/L) was significantly higher than LABC (median 28.9 mg/L). Comparing MIBC
to MBC, MIBC was significantly higher both in all patients (p = 0.005) and in an analysis
restricted to treatment naïve patients (p = 0.002). Interestingly, the IBC patients have
normal levels while the MBC patients have lower than normal levels when untreated (p =
0.039). Likewise, MIBC has significantly higher levels of TGF-β1 than MBC (p = 0.005
in all patients and p = 0.002 in treatment naïve patients). This is particularly surprising
given that recent gene expression micro-array data of laser micro-dissected tumors show
that IBC tumors have attenuated TGF-β signaling (77).
Together with the CRP data and general inflammatory profile, these data
suggest that IBC has more controlled systemic inflammation, possibly mediated by the
anti-inflammatory properties of TGF-β1.

Interestingly, in addition to its anti-

inflammatory properties, TGF-β1 is the prototypical inducer of EMT, the process that
allows tightly clustered epithelia cells to gain migratory and self-renewal abilities while
impeding proliferation.

The CRP data suggesting less inflammation contradicts the

central hypothesis and anecdotal observations from the clinic therefore we are repeating
the CRP analysis using a high-sensitivity clinical test from Siemens.

Preliminary

analysis shows median values of HD = 1.8, IBC = 3.0, LABC = 2.5 MBC = 4.3 and
MIBC = 7.3 with both MBC and MIBC significantly higher than normal.
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Figure 2.4
TGF-β is significantly elevated in IBC. Dotted lines show the 25th and 75th percentile
range of the healthy donors. Bars show the median with interquartile range. Asterisks
indicate significance by Mann-Whitney test at p ≤ 0.05.
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Chapter 3: Inflammatory Breast Cancer Hematology Profile
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INTRODUCTION
The immune system is the body’s defense against potentially harmful cells and
organisms. Everything from viruses to bacteria to multicellular parasites to cancer must
be eliminated or controlled to sustain life. The human body has protective layers starting
with the skin as a protective barrier and progressing down to the single cell level where
multiple pathways have evolved to protected against intracellular attack. However, the
hematopoietic system comprised of red and white blood cells, lymph nodes spleen, bone
marrow and thymus is unique in its ability to circulate throughout the body.
It is thought that the immune system evolved to protect the host against infection.
The mammalian immune system is a highly complex network of specialized and
interacting cells with a seemingly endless array of sub-types. A brief introduction to each
of the major classes is provided prior to discussing them in the context of inflammatory
breast cancer in the following sections.

However, the immune system and the

inflammation it induces have a darker side as there is increasing evidence that
inflammation plays a crucial role in cancer development.
Cancer is a heterogeneous system that has a multitude of interactions with the
microenvironment at multiple steps during tumorigenesis and metastasis. Interactions
with the immune cells at each step of multistage metastasis can be pro-tumorigenic or
anti-tumorigenic. First, as a nascent primary tumor, mutant cancer cells must evade the
immune system that is capable of recognizing and attacking novel antigens that may arise
with the transformation process. As it grows, the tumor requires growth factors and
angiogenic factors that can be autocrine or provided by the microenvironment. Invasion
of surrounding tissue requires degradation of extracellular matrix. Many tumor cells
acquire this invasive phenotype, but macrophages that specialize in tissue restructuring
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can also be recruited. To reach a metastatic site, tumor cells from the primary tumor
transit by way of the blood stream or lymphatic vessels where they must not only survive
the turbulence of transport, but must continue to evade immune surveillance. Only a very
small proportion of tumor cells that enter the circulation are able to survive this process.
Upon reaching the pre-metastatic niche, the tumor cell again must invade the surrounding
tissue that must be conducive to tumor growth.

At each stage inflammation and

regulation of the immune response plays critical. In the 5th chapter of this thesis, we will
provide evidence that inflammatory factors from activated immune cells are capable of
inducing epithelial-mesenchymal transition (EMT) in inflammatory breast cancer cells.
However, in this chapter, we will first try to define the scope of the peripheral immune
system in IBC.

POPULATION STUDIED
In order to establish a hematological profile of peripheral blood cells in
inflammatory breast cancer, we analyzed peripheral blood samples obtained under MD
Anderson protocol Lab08-0199 “Reactivation of Epstein Barr virus in patients with
breast cancer.” This IRB-approved protocol had a planned enrollment of 120 patients
and 30 healthy female donors and was open to patients starting a new line of therapy.
The planned enrollment was for 30 patients with stage III inflammatory breast cancer and
30 patients with locally advanced breast cancer (LABC) (stage IIB or higher) for
comparison. In addition, the protocol was to enroll 30 patients with metastatic breast
cancer with inflammatory features (from here on referred to as metastatic IBC, or MIBC)
and 30 patients with non-IBC metastatic breast cancer (MBC). We hypothesized that
IBC patients would be worse than LABC patients, and that MIBC would be worse than
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both IBC and MBC. Patients were recruited between October 2008 and April 2012 from
the Nellie B. Connally Breast Center and the Morgan Welch Inflammatory Breast Cancer
Research Program and Clinic at the University of Texas MD Anderson Cancer Center.
There was an over-enrollment in the MIBC arm of the study with a dearth of IBC patients
as several patients with metastases were recruited to the Stage III (non-metastatic) IBC
arm of the study. These patients were enrolled prior to staging and were thought to have
locally advanced disease, but due to incomplete staging at the time of enrollment and the
rapid progression of IBC, were subsequently found to have progressed to MIBC at the
time of enrollment. As a consequence, the protocol was modified to increase the number
of allowable MIBC patients. Additionally, 5 patients with secondary IBC were excluded
from the analysis. For this analysis, total enrollments included 32 patients with IBC, 26
patients with LABC, 26 with MBC and 54 with MIBC and 34 healthy female donors
(HD) as controls.
Patient characteristics are presented in Table 3.1 Patient Characteristics on page
17. The healthy donor pool was significantly younger than patients (Student’s t-test, p <
0.001). However we thought it prudent to include younger healthy donors, as IBC is
known to afflict young women.

Indeed, Morgan Welch, the namesake of the IBC

program at MD Anderson, was 24 years old when she died of IBC. Ten of the healthy
donors included in this study were between 24 and 30. Excluding these 10, the mean age
of healthy donors was 46.4 years old, providing a rough approximation to the study
population with no significant difference in age between the pruned healthy donor
population and any of the groups (Student’s t-test > 0.05). There was no significant
difference between IBC and LABC with respect to age (Student’s t-test p < 0.05) or the
distribution of race, tumor grade, subtype (HR+, Her2 amplified or TNBC), (χ2 test p >
0.05), or the administration of prior systemic therapy (Fisher’s Exact test p > 0.05). The
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locally advanced group included 14 patients (54%) with stage II tumors, whereas by
definition, all of the IBC cases are stage III. As such, there is a slight stage mismatch
between IBC and LABC. Additionally, IBC had a significantly higher proportion of
samples with reported lymphatic invasion: 85% of IBC cases noting the presence or
absence of lymphatic invasion were reported as positive vs. 30% of LABC (Fisher’s
Exact test p = 0.0002). It should be noted, however, that dermal lymphatic invasion is a
confirmatory diagnostic criteria for IBC, therefore pathologists examining a suspected
IBC case are specifically looking for the presence of lymphatic invasion. As such, there
can be a bias for the positive reporting of lymphatic invasion in the IBC cases.
Comparing MBC with MIBC, there was no significant difference with respect to
age (Student’s t-test p > 0.05) or the distribution of patient race, tumor grade, lymphatic
invasion, or prior use of systemic therapy (Fisher’s Exact test p > 0.05). As shown in
Table 3.2 Tumor Intrinsic Subtypes in Metastatic Disease, on page 48, MIBC had a
significant enrichment in patients with TNBC tumors (χ2 test, p = 0.0413). This is in
concordance with known studies of IBC (78).

45

Table 3.1 Patient Characteristics for Cellular Studies
Patients in this study were recruited under MD Anderson IRB-approved protocol Lab080199. Patients included locally advanced breast cancer patients with and without
inflammatory features (IBC and LABC, respectively) and stage IV metastatic patients
with and without inflammatory features (MIBC and MBC, respectively). Tumor
subtypes are derived from pathological report, TNBC tumors lacked expression of ER
and PR, and Her2 amplified; tumors were classified as Her2 amplified or Her2+ if they
were IHC 3+ or FISH+; tumors were classified as luminal if they were positive for ER or
PR staining but not Her2 amplified. Abbreviations: HR, Hormone receptor positive IBC;
LABC, Locally Advanced Breast Cancer; MBC, Metastatic Breast Cancer; MBIC,
Metastatic breast cancer with inflammatory features; TNBC, triple receptor negative
breast cancer
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Table 3.1

N
Age
Race

Mean (range)

Asian/Pacific
Islander
African American
Spanish/Hispanic
Caucasian
Stage
II
III
IV
Grade
1
2
3
Treatment Previous Systemic
Status
Therapy
Treatment Naïve
Subtype
Luminal (HR+)
Her2+
TNBC
Lymphatic Positive
Invasion
Negative

IBC
32
54.7
(32-76)
2

LABC
26
51.4
(31-67)
0

MBC
26
54.5
(35-75)
1

MIBC
54
53.0
(31-76)
0

1
2
26
32
1
12
18
3

4
6
16
14
12
3
8
15
2

3
5
17
26
0
7
13
19

4
4
46
54
0
15
37
36

29
9
16
6
22a
4

24
13
9
4
6a
14

7
14
7
5b
8
5

18
15
15
24b
36
3

HD
34
40.7c
(24-60)

a) IBC vs. LABC p < 0.005; b) MIBC vs. MBC, p < 0.05; c) HD vs. all others, p < 0.05
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Table 3.2 Tumor Intrinsic Subtypes in Metastatic Disease
Intrinsic tumor subtypes were approximated by IHC expression patterns and
FISH. There is a significant enrichment of triple receptor negative tumors in MIBC
compared with MBC (χ2 test, p = 0.0413).
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Table 3.2

MBC

MIBC

Luminal
(HR+Her2-)
Her2+

54%

28%

27%

28%

TNBC

19%

44%
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TOTAL PERIPHERAL BLOOD WHITE BLOOD CELL COUNT IS NORMAL IN IBC

White blood counts (WBC) measure the total circulating leukocytes. Normal
ranges are between 4x103 and 11x103 cells/µL. In general, a low WBC can leave a
patient susceptible to infection whereas a high WBC is indicative of an infection or
hematoproliferative disorder but can also increase with smoking or corticosteroid
administration. White blood cell counts also tend to decrease with age. In general, a
total WBC between 3x103 and 11x103 cells/µL of blood is considered normal consisting
on average of 50-70% neutrophils, 25%-35% lymphocytes, 4-6% monocytes, 1-3%
eosinophils, 0.4%-1% basophils.

To get a proper picture, both absolute WBC and

relative (percent) values of individual leukocyte types should be considered. Table 3.3
White Blood Count and Leukocyte Differential – Absolute counts on page 59 and Table
3.4 White Blood Count and Leukocyte Differential – Relative Values on page 61
summarize the data from these studies. The WBC is shown graphically in Figure 3.1
White blood counts in IBC are normal on page 51. The data is presented graphically in
Figure 3.2 White blood count and leukocyte differential on page 63. The table highlights
significant differences between groups. However, for these tables and throughout this
dissertation, differences between IBC and MBC, and LABC and MIBC are ignored as
these are not meaningful comparisons.
Median WBC was (in thousands of cells/µL) 6.80 for IBC, 6.80 for LABC, 5.30
for MBC and 6.80 for MIBC. The average HD WBC was 6.35. MBC had the lowest
WBC, significantly lower than that of HD, IBC, and even MIBC.
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Figure 3.1 White blood counts in IBC are normal
WBC from IBC, LABC, MBC, MIBC and HD are shown as median + interquartile
range. The normal range of 4–11 x 103 leukocytes per µL of blood is shown with dotted
lines. WBC from both IBC and MIBC was not significantly different from normal.
However, the median WBC in MBC was significantly lower than normal although still
within the normal range. 36% of MBC patients were leukopenic with WBC below 4 x
103 cells per µL. Significant differences as determined by Mann-Whitney U test are
denoted by * (p ≤ 0.05), ** (p ≤ 0.01), or *** (p ≤ 0.001).
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WHITE BLOOD COUNT AND DIFFERENTIAL

Looking at total WBC gives only a very granular picture where IBC and MIBC
both appear to be no different from that of HD. However, examining subsets of cells
gives a broader picture. Throughout this chapter we will continue to subdivide peripheral
blood leukocytes into smaller and smaller subsets. In the following chapter, we will look
at a few specific subsets and ask whether there are any functional differences in the cells.
At a first pass, peripheral blood leukocytes can be subdivided in to granulocytes
and agranulocytes. Granulocytes, which include neutrophils, eosinophils and basophils,
are also called polymorphonuclear leukocytes due to the varying shape of the nucleus and
staining of intracellular granules. The most common granulocyte is the neutrophil, the
short-lived, armed-to-the-teeth bacteria killing machine. These cells generally live about
6 days with a circulating half-life of less than a day and are continuously regenerated by
the bone marrow under physiological conditions. Neutrophils are very important as a
first-line defense against infection; however, they have also been implicated in promoting
metastasis.

For example, high neutrophil levels, specifically the neutrophil to

lymphocyte ratio, have been associate with poor clinical outcome in breast (79) and
ovarian cancers (80), as well as nasopharyngeal (80), hepatocellular (81), gastric (82),
colorectal (83), and renal cancers (84).

They can be recruited to the tumor

microenvironment by chemoattratctants or chemokines such as IL-8 (85) or Damageassociated molecular pattern molecules DAMPS such as high-mobility group box 1
(HMGB1)(86) that have been shown to be overexpressed in cancer (87). Neutrophils can
have strong angiogenic activity by the release of matrix metalloprotease (MMP) 9 and
VEGF(88). In vitro, neutrophils can enhance the migration of breast cancer cells in an
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intercellular adhesion molecules (ICAM)-dependent manner (89).

Additionally,

neutrophils are capable of establishing a pro-thrombocytic state through the creation of
neutrophil extracellular traps through the release of DNA (90). TGF-β can polarize
neutrophils towards a pro-tumor N2 (type-2 immune response) state typified by high
levels of arginase 1 and decreases tumor-directed cytotoxicity, whereas lack of TGF-β
signaling can induce anti-tumorigenic N1 neutrophils that activate CD8 cells and are
more cytotoxic (91). Additionally, factors in the microenvironment can extend the life of
neutrophils. Perhaps most provocatively, neutrophils can prepare pre-metastatic sites
prior to the arrival of tumor cells. Using a mouse model of breast cancer, Granot et al
showed that “tumor-entrained neutrophils” (TENs) accumulate in the lung and decrease
tumor seeding efficiency. They showed that neutrophils arrive at premetastatic site prior
to detectable tumor cells; without the TGF-β suppressive effects from the tumor
microenvironment, they are able to acquire an anti-tumorigenic N1 phenotype and are
capable of killing tumor cells (92). In contrast, Yan et al showed that immature myeloid
cells accumulate in the lung and prepare the metastatic niche by releasing MMPs and
promote vascular remodeling (93). Thus, neutrophils are capable of greatly influencing
the natural history of breast cancer.
Eosinophils, named for their affinity for the acidic dye eosin (94, 95) are typically
associated with allergic reactions due to their release of histamine. They are typically
associated with type-II immune responses (which will be discussed in Chapter 4) that
help fight multicellular parasites.

Eosinophils release factors such as leukotrienes

(derived from arachadonic acid), major basic protein, eosinophil cationic protein (which
is similar to porforin), eosinophil-derived neurotoxin, eosinophil peroxidase, CD30L (a
TNF-α family member) and a number of pro-inflammatory cytokines (96). Although
eosinophils have been shown to induce angiogenesis (97) and are active in breast
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development (98), much research is required to understand the possible roles eosinophils
may have in cancer.
Basophils, the least common class of granulocytes, are named for the affinity to blue,
basophilic dyes. They tend to accumulate at site of ectoparasite infections such as ticks
and allergic reactions.

IgE-primed basophils degranulate releasing histamine and

inflammatory factors. As they are targeted to the skin, they have potential relevance in
IBC. Although they arise from different progenitors, basophils in blood are similar to
mast cells in tissue, which have been shown to be immune suppressive (99). The immune
suppressive effects are mediated by IL-10 (100). Mast cells are recruited to the skin via
draining lymph nodes (101) by the chemokine receptor CXCR4 (102). Although the
relevance of mast cells to cancer biology is starting to agglomerate, very little is known
about basophils cells: in fact a Pubmed search of “basophil” and “breast cancer” only
returned 11, mostly unrelated hits.
In addition to granulocytes, peripheral blood leukocytes are comprised of two
primary types of agranulocytes that can be readily distinguished by morphology alone:
lymphocytes and monocytes.
Monocytes are the precursors to the major phagocytic cells of the body. Sharing a
common myeloid progenitor with the granulocytes, monocytes give rise to microglia in
the brain, Kupffer cells in the liver, osteoclasts in the bone and the professional antigen
presenting cells: monocyte-derived dendritic cells (mDC, which can be found in blood
and will be discussed separately). These differentiated cells, and to a lesser extent the
circulating monocytes, engulf pathogens, debris, and apoptotic cells (and bone in the case
of osteoclasts), but they are more than just trash compactors.

Critical to immune

function, after sampling the environment, they process and then present the antigens they
encounter. Antigen presentation is the critical first step in initiating an adaptive immune
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response that allows the immune system to build a memory base to novel antigens. As
antigen presenting cells, they are capable of modulating the immune response by
providing or retracing critical co-stimulatory signals and regulating the cytokine milieu of
the responding cell. These signals produced by antigen presenting cells regulate weather
an immune response is initiated and what type of response is produced. Therefore, these
cells could be critical in regulating the inflammatory environment.
Lymphocytes are derived from a common lymphoid progenitor during
hematopoiesis, separate from the cells discussed, thus far. Generally small, round and
non-descript, lymphocytes in blood are comprised primarily of T cells, B cells and
Natural Killer (NK) cells. These cells will be discussed only briefly here and in greater
detail later. T cells and B cells make up the adaptive arm of the immune system: T cells
are responsible for the cellular response and B cells the humoral (antibody) response.
After leaving the bone marrow, T cells mature in the thymus (and thus the T-cell
nomenclature) where they are “educated.” As discussed later, T-cells respond to antigens
presented by antigen presenting cells such as monocyte and their progeny and can either
elicit a cellular response that can lyse cells including tumor cells, induce an inflammatory
response, or provide growth factors for a B-cell antibody response. In humans, B-cells
remain in the bone marrow during maturation (however, the term B-cell refers not to
bone-marrow, but instead to the bursa of Fabricius, the avain site of hematopoiesis and Bcell maturation that lacks a direct mammalian homologue). Natural killer cells are innate
cytotoxic lymphocytes first described for their ability to quickly recognize and kill “nonself” cells and now recognized to have broader immune effector and modulatory
activities. Therefore the number of lymphocytes in blood could play a role in tumor
control and inflammation.
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Thus, different cell types can contribute to the hematologic state of a patient. As
noted above, MBC has a decrease in total white blood count. Table 3.3 White Blood
Count and Leukocyte Differential – Absolute counts on page 59 and Figure 3.2 White
blood count and leukocyte differential on page 63 show the differential.

In IBC,

peripheral blood counts of neutrophils, lymphocytes, monocytes, eosinophils and
basophils are not significantly different from those of healthy donors. MBC, however,
has significantly lower than normal counts of neutrophils, lymphocytes and basophils (p
= 0.037, <0.001, and 0.017 respectively) than those of HD.

To facilitate viewing

multiple parameters of different scales, each variable in was standardized to the healthy
donors as shown in the “radar plots” on the right side of Figure 3.2 White blood count
and leukocyte differential.
In comparing neutrophil distributions in advanced breast cancer, we observed an
increase in neutrophil counts and relative frequency in IBC, LABC and MIBC but not
MBCs. Notably, MIBC did not have the drop in neutrophils. This may suggest that the
neutrophils in MBC are associated with the protective effect against metastasis as
suggested by Granot (92). However, this is contracted by Kaplan-Meier analysis which
shows that patients with higher than average neutrophil counts (greater than the 95th
percentile of the HD) have decreased overall survival (median survival of 9.0 months for
hi neutrophil counts vs. 34.4 months for average neutrophil counts, p = 0.044 with a
hazard ratio of 2.5).

However, the numbers are very small (7 patients with high

neutrophil count and 5 deaths), and it is likely that the neutrophil count is a surrogate for
infection. Nevertheless, it is noteworthy that a simple blood test can be so illuminating.
All patient groups with the exception of LABC had significantly lower than
normal lymphocyte counts (Mann-Whitney U p < 0.05) and metastatic (M1) patients had
lower than lymphocyte counts than non-metastatic (M0) patients. While there was no
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significant difference between IBC and LABC, this begins to suggest that the hematology
in IBC “worse” than non-IBC and is there is a fundamental difference that makes IBC a
unique entity.

Unique to MIBC (seen as a purple line on the radar plot in Figure 3.2 White blood
count and leukocyte differential), there is a significant increase in monocyte counts
relative to HD, non-metastatic IBC and MBC (p < 0.05). However, while MBC has a
significant drop in WBC as noted above, these patients do not exhibit decreased
monocyte counts.

This is borne out when looking at the relative proportions of

monocytes where MBC has a non-significant trend towards elevated proportions of
monocytes. As monocytes are the precursors of most antigen presenting cells (APC) (i.e.
dendritic cells and macrophages), our results suggest that sufficient numbers of APC to
present to the adaptive arm of the immune system. However, their functional ability to
present antigen will be examined in Chapter 4.
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Table 3.3 White Blood Count and Leukocyte Differential – Absolute counts
White blood cell counts and differentials were collected as part of routine clinical visits.
Data is reported as numbers of cells per µL. The complete white blood count includes
neutrophils, lymphocytes, monocytes, eosinophils basophils and unclassified cells. Both
mean and median are presented. Test statistics are based off the Mann-Whitney U test.
Significant differences are acknowledged by superscript.
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Table 3.3

Disease

Cells per µL
IBC

WBC x 103

Neutrophils

Lymphocytes

Eosinophils

MBC

MIBC

HD

Count

32

26

26

54

34

Mean

6.99

7.07

5.38

6.75

6.89

Median

6.80

6.80d

5.30b,d,g

6.80b

6.35g

Standard Deviation

1.87

2.67

1.98

2.53

2.02

Count

32

26

26

54

34

Mean

4431

4387

3373

4519

4037

b,g

b

3544g

Median

4460

3800

Standard Deviation

1434

2574

1529

2142

1422

Count

32

26

26

54

34

Mean

1898

2060

1387

1459

2220

c,e

d

d,g

c,h

2189e,g,h

Median

1881

Standard Deviation

Monocytes

LABC

1932

2999

1339

4309

1243

608

596

635

827

710

Count

32

26

26

54

34

Mean

463

461

435

575

466

Median

431

c

461

b

b,c,h

446h

Standard Deviation

191

138

218

252

172

Count

32

26

26

54

34

Mean

152

121

138

147

139

Median

100

136

120

88

124

Standard Deviation

129

65

122

210

99

Count

32

26

26

54

34

Mean

28

33

39

30

45

Median

26

29

21g

23h

33g,h

Standard Deviation

15

15

76

24

45

428

516

Basophils

a IBC vs. LABC p < 0.05
b MBC vs. MIBC p < 0.05
c IBC vs. MIBC p < 0.05
d LABC vs. MBC p < 0.05
e HD vs. IBC p < 0.05
f HD vs. LABC p < 0.05
g HD vs. MBC p < 0.05
h HD vs. MIBC p < 0.05
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Table 3.4 White Blood Count and Leukocyte Differential – Relative Values
The relative proportions of peripheral white blood cells are displayed. The complete
white blood count includes neutrophils, lymphocytes, monocytes, eosinophils, basophils
and unclassified cells. Both mean and median are presented. Test statistics are based off
the Mann-Whitney U test.
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Table 3.4
Disease

Percent Total Leukocytes
IBC

Neutrophils

Lymphocytes

Monocytes

Eosinophils

Basophils

LABC

Count

32

Mean

62.6

MBC

MIBC

26

26

54

59.6

62.0

65.9
h

HD
34
57.8

e

61.1

62.8

66.1

Standard Deviation

8.2

10.9

9.8

10.3

7.4

Count

32

26

26

54

34

Mean

28.0

31.1

26.4

22.3

32.6

26.4c,e

30.8

26.2g

21.7c,h

33.3e,g,h

Standard Deviation

7.8

9.1

9.7

9.8

6.7

Count

32

26

26

54

34

Mean

6.6

6.8

8.1

8.8

Median

Median

63.2

6.9

Median

6.9

c

6.5

8.0

Standard Deviation

1.7

2.0

3.3

3.0

1.9

Count

32

26

26

54

34

Mean

2.2

1.9

2.6

2.3

2.0

Median

1.7

2.1

2.0

1.4

1.7

Standard Deviation

1.7

1.0

1.8

2.5

1.2

Count

32

26

26

54

34

Mean

8.7

c,h

57.8e,h

6.9h

.4

.5

.6

.5

.6

Median

.4

e

.4

.4

.4

.6e

Standard Deviation

.3

.3

.8

.3

.5

Count

32

26

26

54

34

Mean

.2

.1

.1

.3

.1

Median

.2e

.0

.0

.0

.0e

Standard Deviation

.2

.2

.2

.7

.1

Other

a IBC vs. LABC p < 0.05
b MBC vs. MIBC p < 0.05
c IBC vs. MIBC p < 0.05
d LABC vs. MBC p < 0.05
e HD vs. IBC p < 0.05
f HD vs. LABC p < 0.05
g HD vs. MBC p < 0.05
h HD vs. MIBC p < 0.05
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Figure 3.2 White blood count and leukocyte differential
White blood counts and leukocyte differentials are depicted for each group. Average
counts and percentages are shown on the left and a standardized “radar plot” is shown on
the right. White blood counts are shown as healthy-donor standardized values by the
equation (µj,i – µj,HD) / (SDj,HD) where µHD is the mean of the healthy donors, SDHD is the
standard deviation of the healthy donors and µi is the mean of IBC (red square), LABC
(blue diamond), MBC (green triangle), or MIBC (purple circle) for each j variable
(neutrophil count, lymphocyte count, monocyte count, eosinophil count, and basophil
count). Each parameter is presented as a radial axis emanating from the center of the plot
with the Z-scaled magnitude of each variable proportional to the distance from the center
of the plot. As the data are standardized to healthy donors, the HD group appears as a
solid black line at 0. A scaled average that is less than healthy donors falls inside the HD
circumference and a scaled average that is higher than healthy donors falls outside the
HD black circumference. Note that statistics presented in the text and tables are based on
non-parametric tests as most variables are not normally distributed; therefore there is no
threshold value on these figures that mark a significant divergence from HD.
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We can conclude that IBC patients have no major deficiencies in there general
classes of leukocytes. This is important to ward off infections and because several
therapies, traztuzumab for example, require the presence of white blood cells for full
efficacy.

In contrast, metastatic patients, both MBC and MIBC, exhibit marked

lymphopenia, and all breast cancer patients show a slight decrease in lymphocytes.
Lymphocyte subsets are discussed below.

LEUKOCYTE IMMUNOPHENOTYPES

As mentioned above neutrophils, basophils eosinophils, monocyte and
lymphocytes can be quickly identified and enumerated based on their forward-scatter
(size) and light-scatter (granularity) characteristics and are routinely observed in the basic
laboratory White Blood Count and Leukocyte Differential. However, to differentiate
lymphocyte subsets such as T, B, and NK cells, as well as dendritic cells, additional
expression patterns must be interrogated. For this study we employed fluorophorelabeled antibody staining with and cell enumeration by flow cytometry to characterize
leukocyte subytpes, which will be discussed following a brief introduction.
Introduction to immunophenotypes
B cells are one of the two main components of the adaptive immune system and
are responsible for producing antibodies. These cells are considered adaptive because
unlike innate immune cells, the receptors on the cell surface recognize antigen and elicit
the immune response are not encoded in the genome and therefore are not immediately
ready to fight an infection or clear mutant cells. Instead, developing B cells undergo
somatic recombination of the B-cell receptor producing a diverse repertoire of mature B
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cell receptors. During development, self-reactive B cells are deleted to limit autoimmunity and other cells wait silently until they are activated. Each B cell has a single,
genetically encoded receptor. When a B-cell is activated by binding its cognate antigen
by the B-cell receptor, the cell proliferates to produce progeny with identical receptors.
B-cells undergo further somatic hypermutation once activated, a process that allows the
population affinity for the antigen to be fine-tuned. Once affinity is optimized, a small
population is converted to a memory B cell and the rest become antibody factory plasma
cells. As such, when first exposed to antigen, adaptive immune cells require time to ramp
up and provide protection, but secondary responses are much faster.
In addition to fighting pathogens, it is widely accepted that B cells play a role in
tumor control as well.

It is well known that many cancer patients develop auto-

antibodies to p53, c-myc and HER-2/neu although they are rarely sufficient to kill
malignant cells (103). This led to the development of one of the first drugs to target Her2
amplified tumors.

The humanized monoclonal antibody traztuzumab, marketed as

Herceptin by Genetech (now a member of the Roche Group), binds to the extracellular
domain of the Her2 protein. This binding interferes with both Her2 heterodimerization
(and therefore mitogenic signaling) and activates antibody-dependent cellular
cytotoxicity (ADCC) (104).
Furthermore, B-cells, by the nature of their highly attuned receptors, act as very
efficient and specific antigen presenting cells. In addition to producing antibodies, Bcells also secrete cytokines. As such, they are capable of shaping the immune response
of a cognate T cell. For example, Breg cells secrete IL-10 and have anti-inflammatory
properties (105).
As there is a flip side to everything, B cells are also capable of promoting cancer.
For example, Lisa Coussens has shown that antibodies to extracellular matrix can
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increase tumor invasion and promote metastasis (106). Immune complexes consisting of
antibodies and complement proteins act as focal points for inflammation. Circulating
immune complexes deposit in the tumor microenvironment due to the leaky vasculature
of the tumor (107-109). These pre-metastatic lesions can require adaptive immune cells
(T-cells and B-cells) to promote innate immune infiltrates that drive full metastatic
progression (109, 110). In addition, B-cell derived cytokines such as lymophotoxin-β
(TNF-β), WNT16 and TNF-α can promote inflammation and tumor growth (111-113).
Finally B cell cytokines such as IL-10 (114) and immunoglobulins (115) are able to
inhibit the TH1 anti-tumor response from T-cells.
As mentioned in chapter 2, T cells are largely responsible for shaping the
adaptive immune response. T cells express a T-cell receptor (TCR) in the cell surface.
Similar to the B-cell receptor, T-cell receptor variability is the result of somatic
recombination resulting in clonal T-cells each with unique antigen specificity. Once
primed, T cells form antigen memory that allows for rapid secondary immune responses.
There are two major classes of T cells: CD8+ cytotoxic T cells (Tc) cells and CD4+ Thelper cells (Th). CD8+ cells are the cytotoxic effector cells have evolved to kill infected
cells by recognizing non-self antigens presented on the surface of infected cells by on
major histocompatibility complex I (MHC-I).

As cancer is often characterized by

genomic instability, novel peptides are frequently produced that can be targeted by CD8+
T cell killing. In contrast, CD4+ Th cells recognize peptides expressed on MHC-class II.
As MHC-II expression is restricted to professional antigen presenting cells, CD4+ cells
do not target the cells they recognize (at least, not for killing). The professional antigen
presenting cells (APC) such as monocytes, macrophages, dendritic cells and B-cells, take
up antigen from the environment and present it to Th cells. Upon recognizing its cognate
antigen, the activated T-cell responds by producing cytokines that “help” the immune
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process which will be explored in the following chapter. However, in brief, type-I
cytokines (TH1) promote the cytotoxic immune response while type-II cytokines (TH2)
promote the humoral response and inhibit the cytotoxic response. A third type of CD4+
Th cell is the regulatory T cell (TReg). These cells inhibit the immune response by
secreting TGF-β and IL-10 and through cell-cell contact through molecules such as
cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1). TReg
require IL-2 and express very high levels of CD25, the IL-2 receptor alpha. TReg typically
express the transcription factor FoxP3 but can be enumerated by cell surface markers
alone as CD3+CD4+CD25brightCD127- as shown in Figure 3.3 FACS Analysis of
Leukocyte Subsets.

Like CD8 cells, NK cells are cytotoxic lymphocytes capable of killing non-self,
virus-infected, or abnormal cells. In contrast to CD8+ cytotoxic T cells (Tc) that must
first be primed, NK cells do not require priming and are capable of killing nearly
immediately.

Although NK cells are innate cells, incapable of the genomic

rearrangements of T and B cells of the adaptive immune system, it would be
inappropriate to consider them a more primitive cell type. In fact, many NK receptor
families are not seen outside of mammals (116, 117) suggesting that NK cells in their
modern form evolved after T cells. There are over a dozen NK activating and inhibitory
receptors that recognize the major histocompatibility complex Class I (MHC I), but each
NK cell expresses only a subset of receptors.
There is no single marker to adequately define NK cells. Typically for human
cells, once CD3+ T cells are excluded, the remaining CD56+ lymphocytes are often
considered NK cells. CD56, also known as Neural Cell Adhesion Molecule (NCAM), is
involved in cell adhesion and may play a critical role in human NK cell development
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(118). However, it should be noted that CD56 is not expressed by mouse NK cells and
therefore is not the definitive NK marker. For clinical tests, NKs are typically stained
with a cocktail of antibody reagents consisting of anti-CD56 (NCAM) and anti-CD16
(the low affinity FcγIII receptor that facilitates binding and recognition of IgG
immunoglobin). This cocktail captures both the CD56+ NK and the rare CD56- subset
that has been shown to be functionally impaired (119). The two primary subsets of NK
cells identified based on their expression of CD56: CD56bright and CD56dim. CD56bright NK
cells are developmentally immature and constitute about 10% of NK cells in peripheral
blood but are enriched in secondary lymphoid organs.

They generally lack CD16

expression (and are therefore incapable of antibody-dependent cellular cytotoxicity) and
have low cytotoxicity, but produce copious amounts of cytokines such as IFN-γ, TNF-α
and granulocyte colony stimulating factor (G-CSF). For their ability to secrete cytokines,
CD56bright are occasionally referred to as regulatory NK.
As mentioned above, T cells do not respond to free antigen, rather they
require peptides (or occasionally lipids) to be processed and presented on MHC class I or
class II. Only professional antigen presenting cells express MHC class II with dendritic
cells as the most potent. As such, they are critical in determining what antigens T cells
will see and in what conditions and form the critical link between the innate and adaptive
immune system.

Dendritic cells scour the tissue rapidly processing antigen. Once

activated through innate pattern recognition receptors that respond to “danger signals”
(120), they migrate to lymph nodes where they increase their antigen presenting
capabilities and interact with T cells. The most common dendritic cells are derived from
monocytes. In the skin and mucosal surfaces these are referred to as Langerhans cells. In
the blood they are myeloid derived dendritic cells (mDC). mDC are defined by high
expression of HLA-class II (HLA-DR+) and absence of the lineage specific markers for
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other agranulocytes (Lin-), specifically CD3 (T cells), CD14 (monocytes), CD16 and
CD56 (NK), and CD19 and CD20 (B cells). mDC have lack expression of the IL-3
receptor (CD123) and do express the inactivated-C3b complement receptor 4 (CD11c).
A second class of dendritic cell that does not derive from the myeloid line is referred to
as plasmacytoid dendritic cells (pDC). These cells are also HLA-DR+ and Lin-. But in
contrast to mDC, pDC are CD123+ and CD11c- (see Figure 3.3 FACS Analysis of
Leukocyte Subsets). While mDC are the most potent antigen presenting cell, pDC are the
professional IFN producing cells, synthesizing massive quantities of the anti-viral
cytokine IFN-α which has been shown to have strong anti-tumor effects and frequently
used as a anti-tumor therapy (121) but can be immune suppressive (122). As such
dendritic cells are critical in control immune induced inflammation.
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Figure 3.3 FACS Analysis of Leukocyte Subsets
Whole blood was stained with monoclonal antibodies and analyzed by 6-color flow
cytometry. A lymphocyte gate was set based on low light scatter (SSClo) and expression
of the common leukocyte antigen, CD45. Using this lymphocyte gate as an anchor
population (SSClo CD45+), B cells were defined as CD19+ cells and T cells were defined
as CD3+. Within the CD3+ gate, Tc were defined as CD3+CD8+ cells and Th cells as
CD3+CD4+. T-regulatory (TReg) were defined as CD3+CD4+CD25brightCD127-. Within
the CD3-negative population, NK were defined as CD56+ or CD16+. Regulatory NK are
CD56bright (outlined with dotted line). NK cells capable of mediating ADCC (ADCC NK)
are CD16+. Finally, CD57+ NK cells are terminally differentiated NK cells that can no
longer proliferate and produce minimal cytokines. Separately, within the leukocyte gate,
NK cells that also express the T-cell receptor (NKT) were defined as cells that are CD3+
and CD16+ or CD56+. Dendritic cells (DC) were enumerated from total white blood cells
without anchoring on lymphocytes. First, cells that expressed HLA-DR+ (MHC II) but
lacked lineage-specific receptors (Lin-) for T (CD3-), monocytes (CD14-), NK cells
(CD16- and CD56-), B cells (CD19- and CD20-) were first gated to selectively quantify
DC. Within this gate, myeloid-derived DC (mDC) were defined as CD11c+CD123- and
the reciprocal CD11c-CD123+ population was used to quantify plasmacytoid dendritic
cells (pDC).

71

0

102

103

104

0

105

<PE-Cy7-A>: CD45
CD45$
0

10

2

10

3

10

4

10

0

B$

10

T$

3

10

2

10

10 4

NK$

10

<APC-A>: CD56

4

10

3

CD16$
<PE-A>: CD16
10 2

10 3

10 4

10 5

CD4$
<PerCP-A>: CD4

10 2

10 3

10 4

10 5

CD25$
<FITC-A>: CD25

10 5

10 5

0

10 2

NK$

10 3

10 4

10 5

5

NKT$

10 4

2

10

2

0

CD57$
<FITC-A>: CD57
10 4

10 5

10

4

10

3

10

2

0

0

10 3

10 3

2

0

<APC-Cy7-A>: CD4

10 2

3

2

10

0

10

T,Reg$

TH$

0

0

4

10

3

CD4$

10 5

10

0

5

10

10

2

0

10

5

CD16$

10

10

4

CTL$

4

CD56$

<APC-A>: CD56

10 3

<APC-A>: CD3

CD56$

3

CD3$

10 2

10 5

10

10

3

0

0

4

10

2

CD8$

4

0

10

10 5

CD123$
<PerCP-A>: CD123
<PerCP-A>: CD8

<FITC-A>: CD19

72

10

pDC$

10 5

CD19$
10

2

5

10 5

10

10

0

Lin$ <FITC-A>: Lin

0

3

CD25$

2

10

<FITC-A>: CD25

10

mDC$

CD127$

Ly$

3

4

<PE-A>: CD127

SSC$

100K

10

10

CD11c$

SSC-A

150K

50K

4

HLA,DR$

10

<PE-A>: CD16

200K

10 5

DC$

<APC-A>: CD11c

<APC-Cy7-A>: HLA-DR

10 5

250K

CD3$
<PerCP-A>: CD3
0

10 2

10 3

10 4

10 5

10 2

10 3

10 4

As seen in Table 3.5 Distribution of Leukocytes including T-cell subsets, NK
cells and DC subsets on page 78 and Figure 3.4 Distribution of Leukocytes including Tcell subsets, NK cells and DC subsets on page 80, IBC has a significant increase in the
percentage of CD3+ T cells of about 5 percentage points compared to LABC, MIBC, and
HD (p = 0.037, 0.022 and 0.002, respectively). While this change is significant, it is
unlikely to be of biological significance; indeed, the absolute count of T cells is not
significantly different from HD (p = 0.220). Although this is whole blood and not tumor,
it should be noted that the presence of tumor infiltrating T cells is well established as a
positive predictive factor in breast cancer (123).
B cells are reduced in IBC
Instead this number is capturing the reciprocal decrease in CD19+ B cells. A
shortage of B cells is one of the more prominent hematological characteristics of both
IBC and other cancers (non breast: (124-128), after metastatic progression or before.
Both IBC and MIBC have significantly lower percentage of B cells than HD (p = 0.001
and p < 0.001, respectively).
CD4 and CD8 T cells
CD4 relative proportions of CD4 cells are high in IBC compared to HD (p =
0.033) and MIBC (p = 0.008). As the difference is small, this is likely due to the
decrease in B cells noted above.
CD4 counts in metastatic disease, both MBC and MIBC are significantly
depressed compared to HD (p < 0.001) and non-metastatic breast cancer (p = 0.001) and
a similar pattern is seen with CD8 cells; however, IBC and MIBC are not significantly
distinguished from LABC and MBC, respectively.
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Recently, low CD4+ T-cell counts have been reported to be related to poor
survival in both treatment naïve and chemotherapy-treated breast cancer patients (129).
In this paper, they used a cut-off of 700 CD4+ T cells per microliter as the threshold for
severe lymphopenia. Interestingly, Manuel et al showed that in addition to the number of
lymphocytes in blood, the diversity of the T-cell receptor repertoire is also an
independent prognostic indicator factor of overall survival in breast cancer patients. In
this study, they used 23 PCR primer pairs upstream and downstream of VDJ
recombination sites to enumerate the T-cell receptor diversity (130).

With next-

generation sequencing technology, it is now possible to have a much clearer
understanding of this diversity. I will be pursing this field of study as a postdoctoral
fellow.

CD4 cell counts were a significant predictor of progression free survival in breast cancer
patients. The cut-point of CD4+ T cells of 700 was a highly significant predictor of
progression-free survival (PFS) in the whole cohort with a median survival of 10.0
months for CD4 < 700 cells/µL but 23.3 months for CD4 > 700 cell/µL with a hazard
ratio of (3.1, 95% confidence interval 2.7 to 9.70). But CD4 count was not a significant
predictor when looking at IBC, LABC, MBC, or MIBC separately, irrespective of
metastasis, or treatment status, but was significant in both IBC and non-IBC (log rank p =
0.004 and p < 0.001). However, CD4 count was not predictive of overall survival (p =
0.1761). Furthermore, CD4 count failed to remain significant in a multivariate analysis
that included stage (M1 vs. M0), presence of inflammatory features (IBC vs. non-IBC),
hormone receptor (ER, PR) and Her2 status. In this model, only metastasis (HR 6.0 p <
0.001) and IBC (HR 1.7 p = 0.048) remained significant (note using CD4 count as a
continuous variable in Cox multivariate analysis was a significant contributor to PFS).
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T-Regulatory Cells are increased in MIBC
The recent success of TReg target therapies such as anti-CTLA-4 or anti-PD-1
confirms the relevance of T cells in tumor immunity (131-133) and suggests that
restoration of the immune system could promote anti-tumor immunity. It has been
suggested that tumor evoked B-regulatory cells with constitutive high Stat3 can induce
TRegs in breast cancer (134). TReg cells inhibit cellular cytotoxicity responses and therefore
play a key role in the development of immune evasion. In these data, we see that patients
with metastatic disease have higher levels of TReg than HD (MBC and MIBC vs. HD p <
0.001 and p = 0.027, respectively) and higher than patients with non-metastatic disease
(MIBC vs. IBC p = 0.079 and MBC vs. LABC p = 0.026).
TReg require the T-cell growth factor IL-2 and express very high levels of the IL-2
receptor-alpha CD25, which can be shed into circulation (sIL-2Rα) upon activation
without decreasing the activity of IL-2(135). Patients with increased levels of soluble
CD25 (sIL-2Rα) had inferior overall survival. It is likely that these high levels of
sCD25Rα are shed from activated TReg. Indeed, in HD, sIL-2Rα has a strong correlation
with TReg count (Spearman ρ= 0.462, p = .0012). Interestingly, there this correlation is
lost in non-IBC patients (ρ = -0.133, p = 0.364) and reversed in IBC (ρ = -0.242, p =
0.046). However, with the high number of samples that had sub-quantifiable levels of
sIL-2Rα (50.6%), this should be viewed skeptically.
In multivariate analysis including age, stage, IBC diagnosis, ER, PR and Her2
status CD4 count and TReg count, both CD4 and Treg were significant predictors of
progression-free survival and overall survival. For PFS, high TReg had a hazard ratio of
5.0 (95% CI 1.3 – 19.2, p = .018) whereas low CD4 counts had a hazard ration of 2.6
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(95% CI 1.4 – 4.7, p = 0.002). For OS, high TReg counts had a hazard ratio of 2.6 (95%
CI 1.3 – 5.3, p = 0.010) and low CD4 counts had a hazard ratio of 2.4 (95% CI from 1.3 –
4.7, p = 0.009). TReg is a significant predictor of prognosis in both IBC and non-IBC.
This suggests that TReg promote tumor growth by inhibiting T-cell function.

Natural Killer (NK) cells
IBC had significantly higher percentage of CD56dim compared to LABC (p = 0.037) while
LABC had a significantly lower percentage of CD56bright regulatory NK than HD (p =
0.014). Together these suggest that IBC has less cytokine producing NK and a larger
number of cytotoxic capable NK cells. However, as we saw in Chapter 2, IBC also has a
higher level of circulating TGF-β1 that may hinder the cytotoxic potential of these cells.
This would be consistent with mouse data published by Olkhanud et al that shows that
tumor metastasis in the 4T1 mouse model requires TReg (which are enhanced by TGF-β)
to kill NK cells (136). In this model, the authors showed that transferring 4T1 cells to a
NOD/SCID mouse that lacks T and B cells but not NK cells failed to produce lung
metastasis. However, adoptively transferring splenocytes including TRegs or TReg alone
allowed for the establishment of lung metastases. In such a manner, there may be higher
proportions of NK in circulation, but they may be unable to control tumor seeding in the
microenvironment. Furthermore, the cytotoxic potential of the circulating NK cells is
unknown. We have developed NK cytotoxicity tests that can be run on fresh, whole
blood so that circulating soluble factors like TGF-β cellular factors like TReg can be
included in the functional testing and we have just begun to test patient samples. It will
be interesting to see if higher levels of mature NK cells in IBC are fully capable of killing
tumor cells.
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Finally, peripheral blood dendritic cell subsets were enumerated. The percentage
of mDC was significantly lower in IBC (median of 41.5% of Lin-HLA-DR+) than in
LABC (median of 51.8%, p = 0.013). Accordingly, IBC had significantly fewer mDC
than LABC (p = 0.025) and both IBC and MIBC had significantly fewer mDC than HD
(p = 0.001 and 0.004, respectively) as an absolute cell count. Furthermore, IBC, MBC
and MIBC not LABC had significantly fewer pDC than HD (p = 0.014, p = 0.004, p =
0.024 and p = 0.421, respectively).
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Table 3.5 Distribution of Leukocytes including T-cell subsets, NK cells and DC
subsets
Leukocytes were enumerated by FACS as shown in Figure 3.3 FACS Analysis of
Leukocyte Subsets. Each subset is shown first as a relative percentage and as an absolute
count on the following line. Lymphocyte subsets (T, B, and NK) are represented as
percent of lymphocytes with the exception of TReg that are presented as percentage of
CD4 cells. Since they are not lymphocytes, the two dendritic cell subsets, mDC and
pDC, are represented as the percentage of total Lin-HLA-DR+ cells. Significant
differences were determined by Mann-Whitney U test.
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Mean ± SEM by patient group
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Measurement

IBC

LABC

MBC

MIBC

HD

No. Patients

32

26

26

51

34

%CD3 T

79.7 ± 7.3

75.3 ± 7.7

73.9 ± 10.6

75.3 ± 8.7

75.1 ± 6.5

a,c,e

CD3+ T/µL

1517.9 ± 557.1

1557.5 ± 516.3

1023.7 ± 492.5

1100.5 ± 643.0

1681.4 ± 586.8

c,d,g,h

%CD3+ CD4+ Th

52.0 ± 8.6

50.0 ± 7.3

45.2 ± 10.5

45.4 ± 11.4

47.6 ± 7.9

a,c,e

CD3+ CD4+ Th/µL

993.3 ± 397.1

1041.2 ± 396.3

646.4 ± 347.9

687.3 ± 463.4

1064.8 ± 376.7

c,d,g,h

%CD3+CD8+ Tc

21.7 ± 9.7

20.7 ± 5.3

23.4 ± 8.5

24.7 ± 11.0

21.6 ± 6.0

n.s.

CD3+CD8+ Tc/µL

410.5 ± 218.2

424.9 ± 159.9

311.0 ± 162.7

345.0 ± 266.2

483.1 ± 240.2

d,g,h

%TREG in CD4

7.0 ± 2.2

6.7 ± 1.9

9.0 ± 2.7

7.9 ± 2.2

6.9 ± 1.8

d,g,h

TREG/µL

68.8 ± 30.9

69.1 ± 27.4

53.5 ± 27.0

52.5 ± 39.1

73.5 ± 32.1

c,g,h

%CD19+ B

9.5 ± 4.3

10.2 ± 3.9

11.4 ± 6.1

9.0 ± 5.7

12.4 ± 4.5

e,h

CD19+ B/µL

176.2 ± 89.0

211.2 ± 99.2

166.3 ± 128.3

143.1 ± 148.0

292.1 ± 170.7

e,f,g,h

6.0 ± 3.7

6.3 ± 4.4

6.8 ± 5.0

7.3 ± 5.2

6.7 ± 3.6

n.s

108.7 ± 64.3

126.9 ± 81.8

102.4 ± 88.4

101.5 ± 86.5

133.9 ± 68.1

h

0.3 ± 0.3

0.2 ± 0.2

0.5 ± 0.7

1.6 ± 9.2

0.3 ± 0.2

f,d

4.9 ± 7.4

3.6 ± 3.1

7.4 ± 10.3

18.2 ± 103.0

5.8 ± 3.6

e,f,h

40.2 ± 12.1

48.3 ± 10.8

46.8 ± 20.0

42.3 ± 16.2

49.5 ± 11.4

a,e,h

mDC/µL

5.0 ± 3.5

8.2 ± 7.0

7.3 ± 8.8

6.0 ± 5.4

8.3 ± 5.7

a,e,h

%pDC in linneg HLA-DR+

17.9 ± 6.7

21.5 ± 10.2

16.8 ± 8.0

20.2 ± 12.0

20.3 ± 9.9

n.s

pDC/µL

2.2 ± 1.6

3.8 ± 4.9

1.8 ± 1.3

3.8 ± 10.4

3.4 ± 2.2

e,h,g

%CD56

dim

NK

CD56dim NK/µL
%CD56
CD56

bright

bright

NK

NK/µL

%mDC in lin

neg

HLA-DR

+

a IBC vs. LABC p < 0.05
b MBC vs. MIBC p < 0.05
c IBC vs. MIBC p < 0.05
d LABC vs. MBC p < 0.05
e HD vs. IBC p < 0.05
f HD vs. LABC p < 0.05
g HD vs. MBC p < 0.05
h HD vs. MIBC p < 0.05
n.s. no significant difference

Significant
Differences

Figure 3.4 Distribution of Leukocytes including T-cell subsets, NK cells and DC
subsets
Cell counts of peripheral blood agranulocyte (mononuclear) leukocyte subsets were
evaluated in IBC, LABC, MBC and MIBC patients. The top figure shows median cell
counts and the radar plots below show relative proportions on the left and cell counts on
the right. As in the previous figure, the radar plots show standardized values to healthy
donors (HD = 1) so that all subsets are on the same scale. Note that radar plots are
calculated with mean values (to generate a Z-score) and may be affected by outliers. Pvalues reported in the text are from non-parametric tests to correct for this effect.
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Figure 3.5 Progression free survival is decreased in lymphopenic patients
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50

In summary, patients with IBC present a few hematopoietic differences from LABC such
as decreased mDC, increased CD56dim NK and the percent of CD3 cells. However, for
the most part, the hematology of locally advanced disease is fairly normal. Metastatic
disease, however, is characterized by severe lymphopenia that is related to decreased
overall survival.
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Chapter 4: Inflammatory Breast Cancer T and DC Functional
Studies Profile
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INTRODUCTION
As mentioned in Chapter 2, T cells are responsible for shaping the adaptive
immune response. Both CD4+ T-helper cells (Th) and CD8+ cytotoxic are capable of
producing cytokines. However the type and quantity of the response can greatly alter the
inflammatory milieu and weather the immune system promotes immune surveillance to
prevent tumor growth or provides a permissive environment. In Chapter 5, we provide
evidence that the inflammatory immune response can even promote cancer progression
by inducing epithelial to mesenchymal transition.
Upon recognizing its cognate antigen, the activated T-cell responds by producing
cytokines that “help” the immune process, which will be explored in the following
chapter. Type-I cytokines (TH1) promote the cytotoxic immune response while type-II
cytokines (TH2) promote the humoral response and inhibit the cytotoxic response. To a
certain extent, in a fully mature effector cell, these responses are mutually exclusive and
the polarization is fairly implastic. Th1 cells are stimulated by IL-12 and IFN-γ. IL-2 is
generally considered to be a TH1 cytokine, although it is a growth factor for all cells
including TRegs. TH1 cells activate, CD8+ cytotoxic T lymphocyte, NK and macrophages
and thus are generally considered to have potent anti-tumor properties. IL-4 is actively
inhibited in these cells. Th2 cells, in contrast are stimulated by and produce IL-4. Other
Th2 cytokines include IL-6 and IL-10. Recently, a fourth class of Th cells has been
identified.

TH17 cells, associated with killing extracellular pathogens and auto-

immunity, produce large of amounts of IL-17. TH17 cells are induced by TGF-β, IL-6
and IL-1β while IL-23 servers as a renewal factor. TNF-a is produced by all T-cells but
since it is pro-inflammatory, it will be classified as TH1 here.
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It is important to note that the antigen-presenting cell that initiates the T cell
response is not a passive bystander.

On the contrary, in concert with the

microenvironment milieu, three critical signals are provided to the naïve T-cell. First is
the antigen/MHC complex. As the majority of T-cells will have very low affinity for the
antigen/MHC complex, they will not be activated.
After recognizing antigen/MHC complex, T-cells must receive a co-stimulatory
signal from the antigen-presenting cell to ensure that the T-cell is responding to a foreign
of dangerous antigen. Antigen presenting cells express CD80 and CD86 that binds CD28
on the T-cell. Without this signal, the T-cell will become anergic and no longer respond
to antigen stimulation, if in the presence of both signals.
The third signal includes inflammatory signals from the microenvironment. As
the antigen presenting cells is in prolonged, close contact with the T-cell, it can produce
very high local concentrations of cytokines.

Exposure to IL-12 will favor a TH1

response that is associated with anti-tumor activity whereas IL-10 will oppose the TH1
response.
Therefore, to understand the possible role of the immune system in IBC, counting
cells is not sufficient. Here we present functional tests that assess the propensity of Tcells to produce cytokines in IBC. This suggests the TH1, TH2, Th17 polarization. Then
we will look at IBC dendritic cell ability to present antigen by the upregualtion of
costimulation molecules and cytokine production.
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Illustration 4.1 T-cell polarization
Antigen-presenting cells such as dendritic cells process and present antigen to T cells.
The cytokine milieu of an activated naïve T cell determines the polarization the T cell
that will be largely maintained on subsequent activation. TH1 cells synthesize IFN-γ
and other cytokines and are involved in cell mediated immunity and tumor surveillance.
TH2 cells synthesize IL-4 and are involved in the humoral response and are typically
considered to promote tumor survival. TH17 cells synthesize IL-17 and other highly
inflammatory factors to protect against extracellular bacteria but have been implicated in
autoimmunity. TReg cells can be produced in the thymus or induced in the periphery and
produce TGF-β and IL-10 as immunomodulatory factors.
Adapted from
livingwellnessblog. Th0 – Naïve CD4+ T helper cell, Th – Helper T cells, Treg –
Regulatory T cells, IL- Interleukin, TNF-α– Tumor necrosis factor alpha, IFN-γ –
Interferon gamma, TGF-β – transforming growth factor-beta.
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POPULATION STUDIED AND METHODS OVERVIEW
As in Chapter 3, patients were recruited under protocol Lab08-019. Peripheral
blood was obtained from 32 IBC patients, 26 LABC, 26 MBC 54 MIBC and 34 HD
(refer back to Table 3.1 on page).
To test T-cell function and polarization, thawed peripheral blood mononuclear
cells (PBMC, white blood cells consisting of monocytes, T-, B- and NK- lymphocytes
and dendritic cells but depleted of granulocytes and red blood cells by density
centrifugation with soluble factor from serum washed away) were stimulated overnight
with plate immobilized anti-CD3 antibody that activated T-cells by cross-linking the
clustering the T-cell receptor (TCR). Anti-CD28 antibody was added to provide costimulation so that patient antigen presentation is not a factor in the test. The percent of
cells producing cytokines was measured by flow cytometry by blocking golgi transport so
that cytokines accumulate in the cell following synthesis. See Chapter 7 for methods.
Dendritic cell function was measured in two assays.

Both interrogate DC

response following activation through the innate receptors toll-like receptor 7 and 8
(TLR7 and TLR8). TLR7 responds to single stranded RNA in endosomes and therefore
is a good model for stimulation by generic microRNA.

TLR8 recognizes GC-rich

nucleotides (oligo-GC). In the first assay, fresh, whole blood was stimulated for 4 hours
to test for cytokine synthesis. In the second assay, fresh whole blood was stimulated
overnight to test for upregulation of co-stimulatory molecules and activation markers.
IBC T CELL FUNCTION IS MOSTLY NORMAL BUT ENRICHED FOR TC17

The only cytokine with significant differences in synthesis between IBC and
LABC is the percentage of CD4 cells producing IL-10. IBC patients had median serum
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levels of 5.3 pg/mL while LABC had 2.9 pg/mL (p = 0.029). As IL-10 is often antiinflammatory, this is consistent with the higher levels of TGF-β1 observed in serum.
In fact, serum TGF-β1 correlated with the relative proportions of both CD4 and
CD8 cells producing IL-10 (Pearson ρ = .198, p < 0.023 and ρ = .197, p = 0.024,
respectively).

In IBC patients, the CD4 IL-10-serum TGF-β correlation was even

stronger (Pearson ρ = .344, p = 0.007). Furthermore, in IBC patients sIL-2Rα, shed from
activated Th and TReg was also strongly correlated with IL-10 production by both CD4
and CD8 cells (Pearson ρ = .480, p < 0.001 and ρ = .436, p < 0.001, respectively). As
TReg perpetuate the anti-inflammatory signaling of IL-10 and TGF-β, this suggests that
closer study of TReg in IBC are warranted even though no differences in circulating TReg
were observed. However, metastatic disease presents a different picture. CD8 IL-10
producing cells in MIBC are significantly reduced in both relative proportion (p = 0.01
vs. HD and p = 0.017 vs. IBC) and number (p < 0.001 vs. HD and p = 0.004 vs. IBC)
while the proportion of few other T cells are similarly affected. Only IL-4 (another
cytokine that inhibits the cellular response) is reduced in MIBC (p = 0.012).
Compared to healthy donors, IBC cytokine production is fairly normal although
there is a weak trend for IBC T cells to be more reactive. This is consistent with the data
published by Mourali and Levine over 30 years ago (5) and suggests that IBC patients are
not immune suppressed and are capable of producing inflammatory factors in response to
stimuli.
However, upon inspection of the standardized “radar” plots in Figure 4.1 on page
98, two features are prominent. Breast cancer leukocytes are greatly enriched for CD8+
T cells producing IL-17 and to a lesser extend IFN-γ. Compared to HD, IBC had
significantly enriched CD8+ T cells synthesizing IFN-γ (p = 0.032) and a nearly
significant increase in CD8+ T cells producing IL-17 (p = 0.058). However, treatment
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naïve IBC patients had significantly higher proportions of CD8+ T cells that produced
IL-17 (p = 0.045). This is an intriguing finding for IBC.
IL-17 producing T-cells (TH17 and TC17) have recently been described as
separate and unique from the traditionally acknowledged TH1/TH2 dichotomy.

As

originally described, these cells play a critical role in experimentally induced
autoimmune encephalomyelitis (EAE) where they have been shown to be the critical cells
responsible for autoimmune reactions (137). IL-17 knock-out mice are incapable of
inducing an auto-immune response.
There has been considerable controversy over the role of IL-17 in tumor
progression.
For example, IL-17 induces a number of pro-angiogenic factors such as VEGF,
macrophage inflammatory protein-2, and prostaglandin E1 and E2 from tumor and tumor
stromal cells (138).

In vivo, mice with IL-17 overexpression have increased tumor

microvessel density compared with IL-17 -/- mice (138, 139).
Furthermore, although MIBC patients are severely lymphopenic, they do not have
a reduction in these cells. In psoriasis-like skin inflammation, the majority of CD8+ T
cells infiltrating the skin co-express both IL-17 and IFN-γ and are able to orchestrate skin
inflammation (140). As IBC is a skin disease, this can be highly relevant. Recently
classified as Tc17 cells, The IL-17+ CD8 T cells are a strange subset. Although CD8+ T
cells are generally strong cellular killers, TC17 cells have been shown to produce the
highly inflammatory factors associated with inflammation, but lack the cytotoxic effector
molecules such as granzyme B (141). As such, patients with high levels of Tc17 cells
may be subjected to highly levels of inflammation, but have a deficit in the tumor
controlling TH1 response.
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No differences in T cell cytokines synthesis were observed between MBC and
MIBC in all patients or in treatment naïve patients (all p > 0.05). Consistent with the
reduced cellular immunity profile noted above, MIBC patients have significantly higher
percentages of CD8+ T cells that produced IL-10.
Looking at absolute counts of cells (cells/µL) in treatment naïve patients, MBC
consistently (but not significantly) displays fewer inflammatory cells than MIBC
(“inflamocytopenia”?). Notice in Figure 4.1D the green MBC line is clearly “inside” the
purple MIBC line. It should be noted that all absolute counts are essentially derived form
the white blood count (discussed in Chapter 2). Any variance in this measure will
propagate throughout the dataset. With that consideration (and the additional caveat that
the number of untreated MBC patients in this study is very small), this suggests that prior
to treatment, there are more inflammatory-cytokine producing cells in MIBC than in
MBC. Furthermore, TNF-α synthesis in particular seems to be elevated in MIBC relative
to MBC. While this study is performed on blood cells and not on tumor infiltrating
lymphocytes (a protocol to test this has recently opened), and uses polyclonal activation
rather than antigen specific stimulation, this data gives us an idea of how T-cells will
respond when they encounter antigen within the tumor microenvironment: simply that
there are a larger number of cells capable of producing inflammatory factors in IBC. In
Chapter 5 we hypothesize that inflammatory factors derived from these cells such as
TNF-α drive the metastatic progression by promoting epithelial to mesenchymal
transition. A unique response to this increased source of inflammation might contribute
to the distinctive features and rapid progression characteristic of IBC.
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Table 4.1
T cell cytokine production. Peripheral blood mononuclear cells were stimulated
through the TCR with immobilized anti-CD3 antibody and soluble anti-CD28 antibody
overnight to elicit cytokine synthesis. The percentage of cells producing cytokines was
enumerated by flow cytometry. Data are shown as the mean ± s.e.m. percentage of
CD4+ T or CD8+ T cells synthesizing cytokine or standardized to the number of CD4+ T
cells or CD8+ T cells per µL of blood that can produce cytokine upon stimulation.
Statistics are based on the non-parametric Mann-Whitney U test.
a IBC vs. LABC p < 0.05
b MBC vs. MIBC p < 0.05
c IBC vs. MIBC p < 0.05
d LABC vs. MBC p < 0.05
e HD vs. IBC p < 0.05
f HD vs. LABC p < 0.05
g HD vs. MBC p < 0.05
h HD vs. MIBC p < 0.05
n.s. no significant difference
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N
IFN-γ

CD4

TH1
CD8
IL-2

CD4
CD8

TNF-α

CD4
CD8
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TH17

IL-17

CD4
CD8

TH2

IL-10

CD4
CD8

IL-4

CD4
CD8

% pos.
cell/µL
% pos.
cell/µL
% pos.
cell/µL
% pos.
cell/µL
% pos.
cell/µL
% pos.
cell/µL
% pos.
cell/µL
% pos.
cell/µL
% pos.
cell/µL
% pos.
cell/µL
% pos.
cell/µL
% pos.
cell/µL

Mean ± S.E.M.
IBC

LABC

MBC

MIBC

HD

29

25

25

42

26

11.6 ± 6.4
110.8 ± 65.8
16.3 ± 9.1
69.4 ± 54.8
15.4 ± 7.3
158.9 ± 103.3
7.0 ± 5.8
22.8 ± 13.9
22.8 ± 9.9
228.9 ± 123.6
14.3 ± 8.7
51.6 ± 31.7
2.9 ± 1.4
27.6 ± 13.9
2.2 ± 2.3
8.3 ± 8.0
6.3 ± 4.7
63.0 ± 51.1
5.3 ± 4.4
21.3 ± 20.9
2.3 ± 1.3
1.5 ± 1.3
23.4 ± 16.1
5.6 ± 5.7

11.3 ± 6.4
111.4 ± 68.2
14.2 ± 7.7
59.9 ± 32.3
13.0 ± 7.0
138.1 ± 93.9
7.0 ± 6.1
31.7 ± 34.7
21.9 ± 11.1
232.7 ± 150.8
15.9 ± 10.5
69.5 ± 59.3
2.6 ± 1.3
27.1 ± 16.3
2.2 ± 1.7
9.1 ± 8.6
3.9 ± 2.4
43.8 ± 34.0
3.7 ± 2.4
15.3 ± 10.9
2.4 ± 1.6
1.8 ± 1.4
24.4 ± 18.4
8.4 ± 9.1

10.2 ± 6.1
64.6 ± 54.9
13.6 ± 8.6
48.6 ± 43.4
13.2 ± 7.9
94.0 ± 80.6
6.7 ± 5.0
21.2 ± 16.7
20.1 ± 10.9
136.7 ± 107.3
12.2 ± 7.6
38.0 ± 27.5
3.2 ± 2.6
17.5 ± 14.3
2.3 ± 3.2
6.7 ± 9.6
5.1 ± 5.0
29.5 ± 24.7
3.3 ± 2.7
9.6 ± 8.3
2.8 ± 2.1
1.4 ± 1.0
14.6 ± 9.3
4.3 ± 3.4

9.0 ± 6.1
56.8 ± 52.4
10.8 ± 7.2
36.2 ± 41.1
13.5 ± 9.9
81.0 ± 81.9
5.8 ± 5.8
19.1 ± 29.0
19.3 ± 12.0
119.6 ± 111.6
10.2 ± 8.1
33.2 ± 38.8
2.9 ± 1.9
16.9 ± 15.9
1.5 ± 1.5
4.7 ± 5.1
5.2 ± 3.9
30.0 ± 27.9
3.3 ± 2.7
9.7 ± 7.8
2.1 ± 1.5
1.1 ± 0.7
12.2 ± 10.2
3.3 ± 3.0

9.0 ± 5.0
78.5 ± 41.6
11.2 ± 7.2
43.5 ± 32.7
15.1 ± 8.2
139.6 ± 86.0
6.4 ± 6.0
25.4 ± 26.2
22.4 ± 10.5
208.4 ± 110.5
12.7 ± 8.5
49.7 ± 37.5
2.8 ± 1.4
25.5 ± 12.2
1.1 ± 0.9
4.9 ± 4.1
5.7 ± 3.7
55.9 ± 43.1
4.7 ± 2.8
20.0 ± 11.9
2.9 ± 1.3
1.2 ± 0.9
28.3 ± 16.4
4.9 ± 3.4

Sig. Differences
n.s.
c,d,f,h
c, e
c,f
n.s
c,h
n.s.
c
n.s
c,d,g,h
c
c,d,h
n.s.
c,d,g,h
f
c,d,f
a
c,g,h
n.s.
c,g,h
h
c,g,h
n.s.
h

Figure 4.1
T cell cytokine production. Peripheral blood mononuclear cells were stimulated through
the T-cell receptor (TCR) with immobilized anti-CD3 antibody and soluble anti-CD28
antibody overnight to elicit cytokine synthesis. The percentage of cells producing
cytokines was enumerated by flow cytometry. Data are shown as the mean percentage of
CD4+ or CD8+ T cells synthesizing cytokine (A and C, top) or the number of CD4+ or
CD8+ T cells per µL of blood that can produce cytokine upon stimulation (B and D,
bottom). The figures on the first page (A and B) show the data for all patients and the
figures on the next page are restricted to treatment naïve patients. As in previous figures,
the radar plots show standardized values with HD = 1 so that all subsets are on the same
scale. Note that radar plots are calculated with mean values (to generate a Z-score) and
may be affected by outliers. P-values reported in the text are from non-parametric tests to
correct for this effect.
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HD$

DENDRITIC CELL FUNCTION
As mentioned in Chapter 3, IBC has significantly fewer mDC than LABC.
However, the ability of those cells to produce cytokines and present antigen could be
critical to tumor and immune surveillance and the regulation of inflammatory processes
in the tumor microenvironment.
To assess these capabilities in DC, we stimulated whole blood with toll-like
receptor (TLR) 7 and 8 and assayed for cytokine synthesis and surface expression of
costimulatory molecules, activation and maturation markers. In parallel, blood was left
unstimulated to assess constitutive levels of activation. Both myeloid dendritic cells
(mDC) and plasmacytoid dendritic cells (pDC) were evaluated. Cytokines included the
inflammatory cytokine TNF-α, the TH1 cytokines IFN-γ and IL-12 and the antiinflammatory/TH2 cytokine IL-10.

Activation markers included CCR5, which is

expressed on resting DC in the tissue, and CCR7, which helps activated DC home to the
lymph node where they interact with T-cells. Costimulatory molecules CD80 and CD86
provide the crucial second signal to T-cells that licenses T-cell activation. Finally, CD40
is a TNF-receptor family member that ligates CD40L on T cells to activate both cells. As
this full complement of cell types, stimulation conditions and assayed molecules resulted
in a huge amount of data; only the significant differences between IBC and LABC or
MIBC and MBC will be presented.
As seen in Table 4.2 and Figure 4.2 IBC has greater synthesis rates of
inflammatory cytokines and poorer antigen presentation capability. Compared to LABC,
on a per cell basis (as measured by mean fluorescent intensity, MFI), IBC had greater
constitutive amounts of TNF-α synthesis by pDC (p = 0.036). Similarly, compared to
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MBC, MIBC had greater constitutive and TLR-induced synthesis of IL-10 by mDC.
Furthermore, IBC both and MIBC had greater induced expression of the activation
marker CCR7 by both mDC and pDC than the non-inflammatory controls (LABC and
MBC). As IBC is characterized lymphatic invasion, increased expression of CCR7
(which targets DC to the lymph nodes) will tend to bring these inflammatory cells in
contact with tumor.
In contrast, although IBC DCs are more likely to become activated and
migrate to the lymphatic vasculature, they are less likely to initiate a cytotoxic response
when they arrive. As seen in the following table and figure, compared to LABC, IBC has
lower numbers of mDC constitutively expressing CD40, CD80 and CD86 (p = 0.001,
0.011, and 0.017, respectively); lower numbers of cells capable of expressing CD80 and
CD86 (p = 0.038 and 0.043, respectively) after exposure to TLR signaling; and lower
numbers of pDC constitutively expressing CD86 (p = 0.001). Similarly, compared to
MBC, mDC from MIBC express lower levels of CD86 following stimulation.

It should be noted that while increased expression of co-stimulatory molecules
such as CD80 and CD86 show that a dendritic cell is capable of providing the required
“signal 2” to T cells, measurement of these markers does not actually test the cells’
ability to present antigen. An alternative approach would be to pulse DC with a recall
antigen such as tetanus toxoid and measure T cell responsesresponse. Furthermore, while
TLR may be activated in response to antigen in the tumor microenvironment, neither the
DC activation not T cell activation studies here test antigen specific responses.

102

Table 4.2
Dendritic cell function. Peripheral blood mononuclear cells were stimulated through the
toll-like receptor (TLR) 7 and 8 for 4 hours to elicit cytokine synthesis or overnight to
induce expression of stimulatory and activation surface proteins (TLR). In parallel, cells
were left unstimulated to measure constitutive expression levels (US). Marker expression
was recorded as a mean fluorescent intensity (MFI) that correlates with the average
number of receptors expressed on the surface of each cell. The percentage of cells
expressing activation and costimulatory molecules as measure by flow cytometry was
used the enumerate cells per µL with the given expression pattern (#). Data are shown as
the mean ± s.e.m. percentage of mDC or pDC expressing marker or mean ± s.e.m MFI of
the specific marker on mDC or pDC. Statistics are based on the non-parametric MannWhitney U test.
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Mean ± S.E.M.
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n
pDC TNF-α US MFI
mDC IL-10 TLR MFI
mDC IL-10 US MFI
mDC CCR7 TLR MFI
pDC CCR7 TLR MFI
mDC CD80 TLR MFI
mDC CD86 TLR MFI
#mDC CD40 US
#mDC CD80 TLR
#mDC CD80 US
#mDC CD86 TLR
#mDC CD86 US
#pDC CD86 US

IBC

LABC

MBC

MIBC

HD

Sig
Differences

32
249 ± 81
457 ± 289
325 ± 149
552 ± 220
1028 ± 6234
6015 ± 2075
16953 ± 8254
79.2 ± 173.3
4502 ± 3417
999 ± 1329
4843 ± 3541
4609 ± 3554
624 ± 681

26
210 ± 82
388 ± 190
282 ± 124
393 ± 154
797 ± 513
6448 ± 3024
19593 ± 11570
250 ± 512
7227 ± 6552
1921 ± 2045
7725 ± 6839
7989 ± 6905
1648 ± 2169

26
253 ± 103
374 ± 206
281± 119
587 ± 314
1088 ± 770
6896 ± 4017
22444 ± 17519
226 ± 491
6423 ± 7313
1426 ± 1998
7268 ± 8683
7045 ± 8503
921 ± 1190

51
342 ± 638
655 ± 822
449 ± 505
580 ± 447
1036 ± 694
4918 ± 2783
13917 ± 8705
253 ± 6023
4554 ± 401
1106 ± 1465
5929 ± 5405
5693 ± 5155
1744 ± 3948

34
213 ± 80
576 ± 221
377 ± 113
665 ± 592
1009 ± 631
5375 ± 2684
12660 ± 6926
127 ± 216
6638 ± 4240
1651 ± 996
7117± 4244
8126 ± 6151
1257 ± 973

a
b,e,f,g
b,f,g
a,d
a,d
b,c
b,e,f,g
a,c,d,e
a,e,h
a,e,g,h
a,e,h
a,e,h
a,d,e,g

a IBC vs. LABC p < 0.05
b MBC vs. MIBC p < 0.05
c IBC vs. MIBC p < 0.05
d LABC vs. MBC p < 0.05
e HD vs. IBC p < 0.05
f HD vs. LABC p < 0.05
g HD vs. MBC p < 0.05
h HD vs. MIBC p < 0.05

Figure 4.2
IBC dendritic cell function has high inflammatory cytokines and low antigen
presentation. Dendritic cells were assayed in fresh whole blood to determine cytokine
production, activation markers, and antigen presentation capability. The same data are
presented in the top and bottom plots. The top “radar” plot shows Z-score standardized
data to so that all variables are on the same scale. The lower plots highlight differences
between IBC and non-IBC. The left plot shows IBC in red and LABC in blue whereas
the right plot show MIBC in purple and MBC in green. Bars are mean ± s.e.m.
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In summary, there is a trend for inflammatory breast cancer patients to have greater
numbers of cells, both T and DC, capable of producing inflammatory cytokines when
activated. Furthermore, there is an increased prevalence of DC and T cells (possibly TReg)
that produce IL-10 and CD8+ T cells that produce IL-17 (Tc17) suggesting that there
may be a deficit in cell-mediated cytotoxicity. In the next Chapter, we will test weather
activated cells are capable of inducing aggressive features in IBC and non-IBC cell lines.
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Chapter 5: Immune cells induce epithelial to mesenchymal
transition in inflammatory breast cancer cells

109

ABSTRACT
Inflammatory breast cancer is the most insidious form of locally advanced breast
cancer, characterized by diffuse inflammation of the breast. The disease progresses
rapidly with about 1/3 of patients having distant metastasis at staging. However, it is
unknown if inflammation could contribute to the rapid progression associated with IBC.
Here we ask whether soluble factors from activated immune cells are capable of inducing
IBC cells to undergo epithelial to mesenchymal transition (EMT), a cellular program
associated with increased migration and invasion that is necessary for metastasis. We
found that conditioned media (CM) from activated T-cells induces IBC cells to express
many factors related to the EMT program including fibronectin, vimentin,
transglutaminase 2 (TG2) and ZEB1. Interestingly, although invasion and migration
increased, E-cadherin, a cell-adhesion molecule typically expressed in IBC tissue, also
increased following exposure to immune factors. The increased expression of E-cadherin
was observed in 3 of 4 IBC cell lines but in none of the non-IBC lines examined. A
combination of TNF-α, IL-6, and TGF-β was able to recapitulate the EMT induction in
IBC and CM pre-absorbed with neutralizing antibodies against these factors decreased
EMT. These data suggest that release of TNF-α, IL-6 and TGF-β by activated immune
cells are capable of inducing EMT in IBC cells and thus, may contribute to the
aggressiveness of IBC.
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INTRODUCTION

Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced
breast cancer. It is characterized by diffuse erythyma and edema of the breast often
mistaken for mastitis. Yet it is often said that IBC is not a true inflammatory condition,
with inflammation arising from the characteristic tumor emboli blocking the dermal
lymphatics. The tumor progresses quickly often within a few weeks or months and is
often metastatic at diagnosis. The rapid onset of metastasis suggests that tumor cells are
disseminating through the lymphatics or blood at an early stage of disease. However,
although tumor cells are in regular contact with immune cells trafficking through the
lymphatics, they are not killed by immune cells and suggest a blunted or immune
suppressed response. In contrast, Mouliari and Levine postulate that since IBC patients
(referred to as rapidly progressing breast cancer) are able to produce delayed-type
hypersensitivity reactions to standard recall antigens and at least one breast tumor lysate,
that IBC patients may in fact present with an augmented cellular immune response to
tumor (5). However, the effect of this postulated immune response on the tumor cells
and their metastatic potential is only beginning to be explored. Recently, Mohammed
and colleagues showed that when factors secreted by the monocytic cell line U937 are
added to cultures of the IBC cell line SUM149, the tumor cells develop enhanced
migratory and invasive features (142) and increased expression of fibronectin (143).
Activated immune cells are known to produce factors such as TNF-α, IL-6, IL-1β and
TGF-β. These characteristics suggest that immune cells may induce an EMT in IBC.
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EMT is a set of biological processes that occur as epithelial cells loose their
sedentary characteristics and gain a motile phenotype. EMT as described by Elizabeth
Hay (144) is important during physiological roles such as embryogenesis where cells
migrate during gastrulation or neural crest formation (145). Kalluri and Weinburg coin
such processes type I EMT (146) and express genes such as Sox, Snail, and Slug which
encode transcription factors that control EMT. Type II EMT involved in wound repair,
tissue regeneration, and fibrosis is characterized by inflammation. TGF-β signaling is
frequently involved. Neoplastic cells undergoing type III EMT hijack hallmarks of both
of these programs producing a metastatic pathology. EMT is characterized primarily by a
loss of E-cadherin expression. Transcription factors such as Snail (147), Slug (148) and
Zeb1 (149) bind directly to E-box regions in the E-cadherin promoter and repress protein
expression (144).

Twist (150), Mesenchyme Forkhead 1 (FoxC2) (151) and tissue

transglutaminase (TG2) (152, 153) have also been shown to regulate EMT. We have
recently demonstrated that detection of any of these EMT-related transcription factors
(EMT-TFs) in the peripheral blood of breast cancer patients can serve as a surrogate for
circulating tumor cells (CTC) in breast cancer patients (154).
Although cytokines such as TNF-α, TGF-β1	
  (155), IL-6 (156) and IL-1β
have been shown to induce EMT in breast cancer cells, the source of these factors has not
been studied.

In the current study, we activated freshly collected peripheral blood

mononuclear cells (PBMC) from healthy donors (HD) to secrete soluble factors that, in
turn, were added to cultures of SUM149 IBC cells. We found that secreted factors from
activated immune cells are capable of inducing EMT in IBC cells.
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Cytokine Profile of primary human PBMC immune cell conditioned media

To test the ability of primary human leukocytes to induce EMT in IBC cells, we
cultured SUM149 cells in the presence of CM of PBMC cultures.

Bacterial

lipopolysaccharide (LPS), a toll-like receptor (TLR)-4 agonist was used to generate
conditioned media from activated monocytes (LPS-CM). Plate-immobilized anti-CD3
antibody plus soluble anti-CD28 antibody were used to generate conditioned media from
activated T-cells (αCD3-CM).

PBMC were left unstimulated to generate control

conditioned media (US-CM).

Each condition was cultured for 48 hours prior to

harvesting. Cytokine concentrations in the resultant CM samples were measured by
Luminex multiplex bead assay and found to contain high levels of inflammatory
cytokines including TNF-α and IL-6 (Figure 5.1 on page 114). Compared to US-CM, the
αCD3-CM contained at least a 100-fold increase in the following factors: IFN-γ, IL-1α,
IL-1β, IL-2, IL-3, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-13, IL-17, monocyte chemotactic
protein (MCP)-3, macrophage inflammatory protein (MIP)-1β, soluble CD40 ligand
(sCD40L), soluble IL-2Rα/soluble CD25α (sIL-2RA), TNF-α, TNF-β and VEGF. A
100-fold increase or greater was likewise observed in the LPS-CM in the following
cytokines: G-CSF, IL-1α, IL-1β, IL-1 receptor antagonist (IL-1RA), IL-6, IL-10, IL12p40, MCP-3, MIP-1α, MIP-1β, and VEGF. In the 5 culture supernatants of PBMC
activated for 48h with anti-CD3 antibody (αCD3-CM), TGF-β had a modest 1.6-fold
increase; TNF-α had an average 101-fold increase; while IL-6 had an average 347-fold
increase. These data suggest that inflammatory cytokines previously shown to induce
EMT (157) are secreted by activated immune cells.
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Figure 5.1
Activated PBMC secreted EMT-promoting factors. Healthy donor PBMC were
stimulated with LPS, plate-immobilized anti-CD3 and soluble anti-CD28 antibodies or
left unstimulated for 48 hours before conditioned media (CM) were harvested. Cytokine
concentrations in the CM supernatants were measured by Luminex multiplex array in 5
representative HD. (a) Relative expression of 46 cytokines, chemokines and growth
factors. (b) Relative expression of TNF-α, TGF-β and IL-6 in LPS-CM, αCD3-CM
relative to US-CM (solid bars).
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Immune conditioned media induces EMT transcription factors in SUM149 cells
Epithelial to mesenchymal transitions (EMT) have been reported in response to
inflammatory cytokines typically produced by products of activated immune cells such as
TNF-α and TGF-β. To test weather the full milieu of factors secreted by activated
immune cells are capable of inducing EMT, SUM149 cells were incubated with αCD3CM, LPS-CM or US-CM.
To test the effect of immune cells on breast cancer cells, immune CM was diluted 1:4
with IBC media and incubated with established 2D cultures of SUM149 cells for 48
hours prior to evaluating EMT (see Figure 5.2a on page 114). After 48-hours, SUM149
cells treated with αCD3-CM exhibited a mesenchymal or stressed morphology with
elongated projections (Figure 5.2b). Assessment of the SUM149 cells exposed to αCD3CM by qRT-PCR showed at least a 2-fold increase in transcripts of fibronectin, Ncadherin, TG2, vimentin and ZEB1 and slightly less in SNAIL1. Interestingly, although
these increased EMT-related factors are typically associated with decreased E-cadherin
expression, SUM149 cells showed a substantial increase E-cadherin expression in
response to αCD3-CM (Figure 5.2c). However, E-cadherin expression is a hallmark of
inflammatory breast cancer and is typically highly expressed even in stage IV tumors.
These data suggest that soluble factors secreted by activated immune cells are able to
induce EMT in epithelial cells.
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Figure 5.2
Conditioned media from activated healthy donor PBMC induces expression of
EMT-related transcription factors in SUM149. (a) Healthy donor peripheral blood
mononuclear cells were stimulated with LPS to stimulate monocytes, plate-immobilized
anti-CD3 and soluble anti-CD28 antibodies to stimulate T-cells or left unstimulated for
48 hours before conditioned media was collected. These immune CM were added to
established SUM149 cultures at 25% of media volume. RPMI-1640 culture media was
used as a negative control (0) and 2ng/mL TGF-β was used as a positive control.
SUM149 cells were incubated with immune CM for 48 hours prior to mRNA extraction.
(b) Morphological changes are consistent with stress and EMT can were observed at this
time point. (c) Expression levels of EMT-related transcription factors SNAIL and ZEB1,
and TG2 were quantified by Taq-Man® qRT-PCR. αCD3-CM and to a lesser extent
LPS-CM, induced large increases in ZEB1 and TG2.
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Immune conditioned media induces phenotypic changes in SUM149 cells
MCF-7 breast cells were used as a representative epithelial cell line and MDA231 cells were used as a representative mesenchymal breast cell line. Cells were grown
on plastic, trypsinized and embedded in paraffin for immunohistochemistry (IHC)
evaluation, as shown in Figure 5.3 on page 120. MCF-7 cells expressed high E-cadherin
and pan-cytokeratin but lacked expression of vimentin or cytokeratin (CK)5/6.

In

contrast, MDA-231 cells stained for vimentin in greater than 50% of cells while lacking
E-cadherin expression. In these cells, cytokeratins (stained with an anti-CK antibody
cocktail) are localized mostly to the cytoplasm and not at the membrane. Punctate
staining is suggestive of golgi localization.
SUM149 cells treated with αCD3-CM up-regulated the expression of
vimentin and E-cadherin, similar to the gene expression data.

(However, LPS-CM

treated cells showed a slight decrease in vimentin.) Cytokeratin 5/6 staining, typical of
basal-like breast cancers but not the MDA-231 cell line, increased following treatment
with αCD3-CM. Finally, pan-keratin localization to both the membrane and cytoplasm
decreased following αCD3-CM treatment, consistent with decrease in epithelial structure.
Together, the increases in vimentin and keratin 5/6 in conjunction with the decreased
staining from the keratin cocktail suggest that activated immune cells induce breast
epithelial cells to a more basal phenotype.
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Figure 5.3
Immune conditioned media induces phenotypic changes in SUM149 cells. Immune
conditioned media (anti-CD3 CM) was added to established SUM149 cells and cultured
for 2 days (black); MCF-7 and MDA-231 grown in standard media were used as controls
(grey). Paraffin-embedded cell blocks were prepared and analyzed by IHC. Morphology
of the cells is visualized with Diff-Quick stain. The percentage of positive cells is listed
in each image and shown in the bar graph at right. Pan cytokeratin expression is shown
for both percent of cells with membrane localization (top number) and cytoplasmic
localization (bottom number). MCF-7 cells show a characteristic epithelial phenotype
with high E-cadherin, low vimentin, low keratin 5/6 expression and strong membrane and
cytoplasmic localization of cytokeratins. MDA-231 cells are mostly mesenchymal with
low E-cadherin, high vimentin and decreased cytokeratin expression. Following
exposure to CD3-CM, SUM149 cells show increased expression of E-cadherin, vimentin,
keratin 5/6 staining and decreased pan cytokeratin staining. (US-CM, Conditioned Media
from unstimulated PBMC; LPS-CM, Conditioned media from LPS-stimulated PBMC;
αCD3-CM, Conditioned media from PBMC stimulated through the T-cell receptor with
immobilized ani-CD3 and soluble anti-CD28) antibodies.
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Immune Cell conditioned media induces EMT profile in multiple breast cell lines
To test immune induction of EMT in additional genetic backgrounds, immune
CM was added to a panel of breast cancer cell lines. Cell lines included the nontumorigenic cell line MCF-10a, hormone receptor positive MCF-7, triple receptor
negative and highly mesenchymal MDA-231, androgen receptor-positive MDA-453, and
HER2-amplified SKBR3. In addition, several IBC cell lines were evaluated including:
HER2-amplified KPL4, SUM190, and IBC-3 cells. As with the SUM149 cells, immuneconditioned media was diluted 1:4 with IBC media and added to established 2D cultures
of above-mentioned IBC cell lines for 2 days. Cells were also treated with 2ng/ml TGF-β
as a positive control for induction of EMT. All cell lines were treated with the same pool
of conditioned media. Cells exposed to immune CM are generally less dense and appear
spindly and stressed.

To test for EMT-inducing transcription factors, RT-PCR was

performed on mRNA extracted from the cell lines using the Fluidigm® Integrated Fluidic
Chip Dynamic Array system to array the samples and the Fluidigm® BioMark™ HD for
thermocycling and data acquisition. Results are summarized in Figure 5.4. In general,
most cell lines showed increases in expression of EMT-related factors following
treatment with immune CM. ZEB1 and TGM2 were the most induced factors along with
the inflammatory factors prostaglandin E (PGE) and IL-8. Consistent with an induction
of EMT, epithelial cell adhesion molecule (EpCAM) expression decreased with αCD3CM treatment in every cell line except SUM149. However, as shown in Figure 5. 5, the
EpCAM response is attenuated in all of IBC cell lines (p=0.0197). Likewise, although
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the non-IBC cell lines showed no change in E-cadherin expression at this time-point, 3 of
the 4 IBC cell lines (SUM149, SUM190, IBC3 but not KPL4 cells) showed a paradoxical
increase in E-cadherin expression (p = 0.0411). Her2-amplification was also associated
with an attenuated EpCAM response (p = 0.210 when SUM149 cells were removed from
the analysis); however, it must be noted that 3 of the 4 Her2+ cell lines in this study are
IBC cell lines and 3 of the 4 IBC cell lines are Her2+. Comparing intrinsic molecular
subtypes, luminal cells had a higher induction of Forkhead box protein C2 (FOXC2) than
the basal-like cells MCF-10a, MDA-MB-453, and SUM149 cells following treatment
with αCD3-CM (p = 0.0384) (although MDA-453 is TNBC, it is androgen receptor
positive and not basal-like) (158-160). While these data confirm that immune induction
of EMT is common among a range of breast cancer subtypes, IBC cells have an abnormal
response characterized by a shift towards EMT while maintaining or increasing
homotypic adhesion.
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Figure 5.4
EMT induction by immune conditioned media is not unique to IBC. Immune
conditioned media from a single healthy donor was added to 2-day old cultures of 9
breast cancer cell lines. Thereafter, mRNA was isolated from the cultures and analyzed
by qRT-PCR using TaqMan® hydrolysis probe assays on the Fluidigm® BioMarkTM HD
system using a single 48.48 Dynamic Array Integrated Fluidic Circuit “chip”. Data are
represented as 2-∆∆Ct fold change with the unconditioned media for each cell line serving
as the reference sample and GAPDH as the endogenous control. Unconditioned media
appears as a solid black line at 1 in the center of each plot; points falling outside or inside
the black solid circle represent increased or decreased relative expression, respectively.
αCD3-CM induced EMT-related transcription factors to varying degrees in all cell lines.
Zeb1 and TG2 are the most consistently increased EMT-related factors across cell lines
and are highlighted with asterisks.
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Figure 5. 5
IBC has unique response to immune conditioned media. Following treatment with
αCD3-CM, IBC cell lines IBC-3, KPL4, SUM149 and SUM190 had a decrease in
EpCAM mRNA compared to those of non-IBC cell lines and with the exception of
KPL4, that had increased expression of E-cadherin.
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Immune CM has minimal effect on mammosphere formation
To test the functional changes associated with exposure to immune conditioned
media, SUM149 cells were placed into mammosphere media following 2 day preincubation with CM, as above. Sphere forming efficiency in mammosphere media allows
for enumeration of cells with the stem cell properties of self-renewal and differentiation
potential (161, 162) that are associated with EMT (163). Cells are added as a single cell
suspension and grown in 3D. After 1 week, “mammospheres” are counted. As shown in
Figure 5.6 on page 129, there was a non-significant trend towards increased sphere
formation following incubation with αCD3-CM (0.43% vs. 0.50%, p = 0.256).
Interestingly, the spheres forming from the αCD3-CM were significantly smaller than the
spheres from cells grown in unconditioned control media (mean ± sem 175µm ± 5.7 µm
vs. 150µm ± 9.6, p = 0.048). This suggests that while EMT and stem cell-like properties
may be induced by exposure to immune activated CM, proliferation is significantly
inhibited, at least in short-term cultures.
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Figure 5.6
Immune conditioned media has negligible impact on mammosphere forming ability.
SUM149 cells were pre-treated with conditioned media and placed into mammosphere
media. There was no significant increase in mammosphere formatting efficiency by
immune conditioned media; however, there was a trend for αCD3-CM to have a higher
sphere forming efficiency.
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Real-time cell analysis reveals increased migration, invasion and adhesion following
incubation with immune conditioned media.
Changes in transcription factors could be identified following 48 hours of
incubation with immune conditioned CM. To understand the kinetics of this change,
real-time analysis of cell growth was measured using the xCelligence real time cell
analyzer (Acea Bioscicens, Inc, San Diego, CA). This technology measures resistance to
the flow of ionic electrical current (impedance) between electrodes laid out in a grid on
the bottom of cell culture well in contact with the growing cells. Measuring electrical
impedance is both non-invasive and label free. Impedance increases with a number of
factors, primarily cell growth and adhesion. As the surface area covered by the growing
cells increases, there is less free surface area on the electrodes for the free flow of current.
Similarly, as the cells adhere more closely to the substrate and to each other, impedance
increases as ions cannot access the electrode beneath the cell (164).

The xCelligence

system measures this impedance at a defined base-line and calculates changes as a cell
index (165). As such, the system can measure cell growth and adhesion, and with a
modified Boyden chamber plate with the electrodes on the bottom of the membrane,
migration can be measured as well as cells migrate unto the electrodes.
Following addition of immune CM, changes could be detected within 10 hours
(Figure 5.7 on page 133).

Interestingly, although αCD3-CM clearly decreased cell

counts by the traditional trypan blue exclusion counting method (Figure 5.8 on page 135),
the real-time analysis showed a marked increase in the Cell Index. In fact, in 2 days,
8x103 αCD3-CM treated SUM149 cells achieved a cell index about 2 times larger than
20x103 SUM149 cells allowed to grow in IBC media for 5 days. (20 x103 SUM149 had a
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cell index of 2.54 after 22 hours of attachment and achieved a maximum cell index of
3.09 at 70 hours, post seeding. In contrast, 8x103 αCD3-CM-treated SUM149 had a cell
index of 1.20 after attachment that rapidly increased to 3.1 within 14 hours of treatment
and 6.07 within 43 hours of treatment). As the Cell Index measured by the xCelligence is
affected by cell morphology and adhesion in addition to cell growth, these data suggest
that immune CM-exposed IBC cells adhere more tightly. This increased adhesion is
consistent with the observed increase in E-cadherin expression by IBC cell lines.
The increase in E-cadherin and EpCAM in IBC cells concurrent with the
upregulation of EMT factors is inconsistent with current models for EMT. We therefore
tested the migratory ability of SUM149 cells exposed to immune conditioned media
using the xCelligence system.

Using a CIM (cellular migration/invasion) plate we

measured SUM149 cell migration towards fetal bovine serum (FBS, a common
chemoattractant) following exposure to immune conditioned media. The SUM149 cells
show a very rapid increase in the cell-index of αCD3-CM-exposed cells suggesting an
induced migratory capacity (Figure 5.7). Similar migration patterns were observed when
the plates were pre-coated with 15% MatrigelTM and when cells were pre-treated with
immune CM for 48 hours and loaded into the chambers in equal numbers (data not
shown). Combined, these data show that the induced changes in IBC cells paradoxically
increase both adhesion and migration.
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Figure 5.7
Immune Conditioned Media induces adhesion and migration in SUM149. SUM149
were grown on an xCelligence® E-plate at an initial density of 5x103/well and exposed to
αCD3-CM, LPS-CM and US-CM at time 0. Cell index, a statistic that summarizes cell
number, viability, and morphology, is measured at 15-minute intervals. The cell index
was standardized at the vertical line, prior to adding the CM that can be seen on the graph
as a transient spike in cell index. Robust changes are observed at 9 hours after treatment
with cells exposed to αCD3-CM showing rapid increases in cell index. To quantify
migration, 50x103 SUM149 cells in immune conditioned media were seed into the top
wells of xCelligence CIM plates with FBS as a chemoattractant in the bottom wells.
Migration is measured as an increase in impedance as cells migrate into the lower
chamber. Migration towards FBS is enhanced by immune activation factors. αCD3-CM
(blue line) induces rapid migration of SUM149 cells. LPS-CM enhancement of
migration (green line) is noted from 7 to ~36 hours, but is not significantly different from
controls (US, Media, no FBS; red, pink and light blue) at later time points. Error bars are
one standard deviation.
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Figure 5.8
Immune Conditioned media decreases tumor cell proliferation. Cells were seeded
into 6-well plates at an initial titer of 75x103 cells per well. After 2 days for cell
attachment, CM was added to each well. Following 2 days of culture with immune
conditioned media, cell titers were determined by determining viable cell counts using
the trypan blue exclusion method. Cells exposed to αCD3-CM had cell counts lower
than the initially seeded cells and lower than LPS-CM, US-CM or media control. Both
LPS-CM and αCD3-CM induced a fibrolblast-like cell morphology with longer
projections and less of a cobble-stone appearance.
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Neutralizing TNF-α , TGF-β and IL-6 reverses immune induced EMT
Factors such as TNF-α, TGF-β and IL-6 have been associated with EMT
induction were found elevated in cells exposed to αCD3-CM. TNF-α induces signaling
through NF-κB and IL-6 induces signaling through Stat3. Therefore, if IBC cell cells are
responding to TNF-α and IL-6 in the conditioned media, we would expect to see elevated
levels of phosphorylated NF-κB (p65), the upstream IκB, and Stat3 in IBC cells
following addition of immune conditioned media. We measured phosphorylation levels
of Stat3 (Ser727), Stat3(Tyr705), IκB (Ser32) and the p65 subunit of NF-κB (Ser536) in
SUM149 cell lysates using Luminex multiplex polystyrene beads (Figure 5.9). αCD3CM and LPS-CM induced Stat3 and NF-κB phosphorylation in SUM149 cells within 1
hour that subsided over 2 days (the time course of the co-cultures shown above). This
supports the hypothesis that IL-6 and TNF-α are acting on the SUM149 cells.
As shown above, addition of TNF-α, TGF-β, and IL-6 synergistically induced
EMT in SUM149 cultures. Therefore, we hypothesized that reducing these factors would
mitigate the induction of EMT by immune activation. To test this hypothesis, αCD3-CM
was pre-absorbed with neutralizing antibodies prior to incubation with SUM149 culture
and EMT-related transcripts were quantified, as before. Compared with αCD3-CM, the
pre-absorbed CM showed a reduction in E-cadherin, EpCAM, fibronectin, N-cadherin,
SNAIL2, TG2, vimentin and ZEB1 (see Figure 5.10 on page 140). This suggests that
TNF-α, TGF-β and IL-6 are partially responsible for the immune changes observed in
IBC cells.
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Figure 5.9
Immune conditioned media activates TNF-α, and IL-6 pathways in SUM149.
Immune conditioned media (αCD3-CM, LPS-CM, US-CM, and media control) were
added to established SUM149 cultures. Cell lysates were collected after 10 min, 30 min,
60 min and 2 days before being analyzed using Millipore Milliplex MAP polystyrene
beads and quantified by mean florescent intensity (MFI) using the Luminex analyzer (the
48 hour sample was only analyzed for αCD3-CM and media control). Phosphorylation
of Stat3 Ser727 and Tyr7005 were measured from the IL-6 signaling pathway and
phosphorylation of IκB Ser32 and NF-κB p65 Ser536 were measured from the TNF-α
pathway. The MFI of each analyte was corrected with the GAPDH loading control for
each sample to account for loading variation. All four analytes show increased
phosphorylation following addition of conditioned media from αCD3 and LPS activated
PBMC but not unstimulted PBMC or control media.
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Figure 5.10
TNF-α, TGF-β and IL-6 induce EMT in SUM149. a) TNF-α, TGF-β and IL-6 were
added to established SUM149 cultures and assayed for EMT-TF, as before. All three
cytokines act additively to induce EMT-TF. b) Neutralizing antibodies against TNF-α,
TGF-β and IL-6 were added to αCD3-CM prior to incubating with SUM149 cells.
Compared to αCD3-CM without neutralization, EMT-TFs were reduced.
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Patient Data
To determine whether increased cytokine production by activated immune cells is
correlated with the induction of EMT in breast cancer patients, we compared the ability
of peripheral blood T cells to produce TNF-α with the expression of EMT-transcription
factors in blood (EMT-CTC). Fresh 5 ml whole blood samples were depleted of CD45
leukocytes and subjected to RT-PCR analysis for the measurement of EMT-related
transcription factors. Matched thawed archived peripheral blood mononuclear cells were
stimulated overnight with plate-bound anti-CD3 and soluble anti-CD28 antibodies for
measurement of intracellular TNF-α synthesis as measured by flow cytometry (166, 167).
Matched data were evaluable from 16 breast cancer patients. Six patients had detectable
EMT-CTC. Of these, 5 had greater than 220 CD3+ T cells per ml of blood capable of
producing TNF-α upon activation (Fisher’s Exact test p = 0.036). Although the numbers
are very small, as seen in Table 5.1, higher numbers of TNF-α producing CD3+ cells are
associated with an increase in EMT-CTC in breast cancer patients. However, a CD3TNF count greater than 225 was associated with longer progression-free survival (p =
0.001).
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Table 5.1
T cells producing TNF-α correlates with EMT-CTC in patients. As shown in
Chapter 4, patients PBMC were stimulated through the T-cell receptor overnight and
interrogated for intracellular TNF-α synthesis by multiparameter flow cytometry.
Additionally, 5 mL of blood was depleted of CD45+ leukocytes to enrich for circulating
tumor cells and interrogated for expression of EMT-related factors. There was a
significant correlation between the detection of at least 1 EMT-related factor in the CTCenriched fraction and presence of 225 CD3+ T-cells per µL of blood capable of
producing TNF-α. A cut-off of 225 cells per µL was established by receiver operator
curve analysis.
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CD3 Cells producing TNF-α

EMT CTC

<225

>225

Total

no EMT

9

2

11

any EMT

1

4

5

Total

10

6

16

χ2 Fisher Exact test p = 0.036
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Discussion
	
  
Here we show that inflammatory breast cancer cells respond to inflammatory
signals from innate and adaptive immune cells with a program reminiscent of EMT that
renders the tumor even more aggressive. We used PBMC from healthy donors activated
with LPS and immobilized anti-CD3 plus soluble anti-CD28 antibodies as a model for
inducing inflammation. To mediate cell-cell killing effects from HLA-mismatch, we
collected only the conditioned media from the activated cells and applied it to established
cultures of IBC cells.

In this model, SUM149 cells respond to immune induced

inflammation with increased EMT factors as shown by PCR, stem cell properties as
shown by mammosphere formation and migration as shown with the real-time cell
analysis. Paradoxically, unique to IBC, these changes were also associated with an
increase in E-cadherin, EpCAM, and cell adhesion, all hallmarks of IBC.
TNF-α levels in the conditioned media of anti-CD3-stimulated PBMC
were higher in than LPS conditioned media. As TNF-α is known to induce EMT, this
can partially explain the superior increase in EMT induction by anti-CD3-stimulated
PBMC. The differences in induced TNF-α levels may be related to cell number as T
cells out-number monocytes in PBMC by about 4 to 1. In fact, untreated IBC patients
have significantly more monocytes than non-IBC patients.

While CD4+ and CD8+ T cells are capable of producing copious amounts
of TNF-α and thus inducing EMT, our data show that T cell synthesis of TNF-α is
positively correlated with survival. This study used immobilized anti-CD3 antibody to
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polyclonally activate peripheral blood T cells non-specifically through the T-cell receptor
in both the enumeration of TNF-α producing T-cells in IBC patients and for the
production of conditioned media from healthy donors. These cells may not have the
same cytokine response as tumor-infiltrating lymphocytes that conditioned the cytokine
milieu in vivo (168, 169). Conversely, parallel studies on TNF-α production by TLRactivated peripheral blood dendritic cells were associated with shorter survival.
Together, these observations suggest that although immune cells are capable of inducing
EMT and potentially metastasis, the immune surveillance, particularly that provided by
the adaptive immune system, may offer an important barrier to disease progression.
Indeed, a recent Van Laere et al report showed that a gene signature associated with a
TH1 immune response was associated with attainment of a pathological complete
response in IBC patients (170).

E-cadherin has represented a conundrum in IBC research. In most carcinomas,
loss of E-cadherin is associated with advanced disease and increased invasion and
metastasis as the homotypic cell adhesions are decreased. IBC, in contrast, has been
shown to have high levels of E-cadherin expression despite the rapid progression of the
disease. In fact, tight clusters of tumor emboli are a hallmark of the disease.

In this study, we showed that E-cadherin expression increased in IBC cell lines
after exposure to αCD3-CM.

This is in contrast to the typical loss of E-cadherin

expression at metastatic progression. In experimental systems, loss of E-cadherin can
induce increased invasiveness and metastasis. As a cell-adhesion molecule, expression of
E-cadherin on the cell surface prevents cell motility, invasion and metastasis. However,
loss of E-cadherin also increases several mitogenic signaling cascades including mitogen
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activated kinase (MAP) and rat sarcoma viral oncogene (Ras).

Conversely,

reintroduction of E-cadherin expression in poorly differentiated cell lines can restore an
epithelial phenotype (for review see F.J. Rodriguez et al (171)). Furthermore, E-cadherin
can increase stem cell viability through upregulation of apoptotic inhibitory gene Bcl-XL
and inhibiting Caspase-3 (172).

However, inflammatory breast cancer tumors typically express high levels of Ecadherin despite the highly aggressive nature and rapid progression of the disease.
Although E-cadherin expression at the protein expression is elevated, mRNA levels are
lower than other E-cadherin positive breast cancers due to altered protein trafficking
(173). Additionally, although IBC is typified by high levels of E-cadherin, constitutive
SUM149 expression is low but can be increased with treatment with EGFR-targeted
therapy as shown by Ueno and Zhang (73).

In our survey of 9 breast cancer cell lines, we found that E-cadherin expression
increased in 3 of the 4 IBC cell lines following exposure to immune factors. In contrast,
none of the non-IBC cell lines showed a similar increase. It would be interesting to
check in the NF-κB, SMAD or Stat response elements in IBC E-cadherin promoters are
different from non-IBC (this is relatively easy to check in silico once a full sequence is
available for IBC cell lines).
The data here showed that spiking IL-6 into the media had little effect on the
induction of EMT, yet depleting it form the conditioned media drastically reduced the
observed EMT at the 2 day time point. The real-time cell analysis experiments were not
performed with neutralizing antibodies due to the difficulty in handling the cells in small
volumes, but it might this might be a good tool for exploring this observation. It is
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possible that IL-6 has a minimal effect in inducing EMT but has a strong effect in
maintaining the EMT-like state. For example, it has been shown that IL-6 is critical for
maintaining and expanding a cancer-stem like population of trastuzumab resistant cells
(63). The data here suggest that multiple pathways need to be blocked to prevent EMT
induction but preventing the maintenance of this state might be a better target. Timebased experiments such as the real-time cell analysis can test this hypothesis.
NF-κB signaling has been shown to induce EMT including down-regulation of Ecadherin through ZEB1 in MCF-10a cells (174). Interestingly, the number of CD3+CD8+
cytotoxic lymphocytes producing TNF-α was correlated with the measurement of EMT
in the blood of breast cancer patients, but the number of CD3+CD4+ T-helper cells was
not. Despite the fact that CD8+ T cells are capable of direct tumor lysis, this observation
is consistent with previous work by Santisteban et al that showed that immune-editing by
CD8+ T cells can induce EMT in a mouse Her2/neu transgenic model (175).

One of the major factors upregulated in αCM-CM is IL-17. IL-17 has been
associated with auto-immune reactions as might be induced by tumor-immune
interactions. However, one of the major targets of IL-17 is endothelial cells. This highly
inflammatory cytokine induces endothelial cells in-turn to produce inflammatory factors
IL-6, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony
stimulating factor (GM-CSF), IL-1β, TGF-β1, TNF-α, IL-8 and MCP-1, many of the
same factors discussed here (176, 177). IL-8 in particular has been shown to supports
breast cancer stem cells in a SUM149 model (65, 66). As the frequency of lymphocytic
infiltrates in IBC tumor emboli is still uncertain, this model allows for the possibility that
immune activation could produce factors such as IL-17 that, in turn, release EMT-related
factors TNF-α, IL-6 and TGF-β1 into tumor emboli.
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Further studies are needed to show that cytokines from activated immune
cells increase metastasis in vivo. However, the patient data presented here suggest that
therapeutic options should not broadly target immune cells. Rather, therapies that alter
the immune response by favoring adaptive immune responses or shifting antigen specific
responses towards a TH1 polarization would be more beneficial.
It can be argued that the phenomenon presented here is a selection of resistant
cells rather than the induction of EMT. Inflammatory factors (such as TNF-α) induce
cell death in the majority of cells and select for resistant cancer stem cells that are
characterized by EMT phenotypes (163). In fact, our data confirm that αCD3-CM
greatly reduces cell counts. However, the kinetic data from the xCellignce platform
suggest selection of resistant cell is unlikely to account for the increase in EMT
phenotype as the cell index increases within just a few hours following addition of
immune-CM to the culture of SUM149 cells, far faster than stem cells would be able to
repopulate a nascent niche evacuated by recently killed differentiated cells.
The combination of increased invasion and increased adhesion is observed
with the xCelligence platform and suggested by the PCR data is confusing but not
unprecedented. The increased cell index has also been reported in the benign prostate
hyperplasia cell line BPH-1 in response to TGF-β1 (178) using this platform. The
authors argue although TGF-β1 has anti-proliferative effects, the induction of EMT
induces cell spreading that increase cell index.
Twist is one of the primary transcription factors responsible for driving
EMT, yet we did not observe a consistent change in Twist expression in this study.
However, redundancies in signaling pathways make single nodes dispensable.

For

example, developmental models in drosophila showed that only the complete loss of both
snail and twist abrogated mesenchymal features (179) and therefore lack of induction of a
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single transcription factor should not imply that the developmental program is not
induced.

Notably, while Twist is required to maintain the EMT program, Twist

expression is dispensable in the early stages of EMT initiation. In fact, Tran et al.
showed that under transient TGF-β1, Snail1 actively represses Twist1 expression, which
later increases. They show that in MCF-10a cells after 2 days of TGF-β1 treatment, the
time point used in the majority of experiments in this study, twist1 expression is lower
than in untreated cells (180).
TGF-β can be a powerful inducer of EMT. Cell culture experiments first showed
that TGF-β induced EMT in mouse mammary epithelial cells. Miettinen et al showed
that TGF-β decreased epithelial markers E-cadherin, desmoplakin I and II and ZO-1
while increasing fibronectin and cytosketal rearrangements. TGF-β1, TGF-β2 and TGFβ3 are all capable of inducing EMT (181).
After binding TGF-β, TGF-β type II receptors phosphorylate the TGF-β type I
receptor(182) and dominant negative forms of TGF-β type II receptor can inhibit
mammary EMT in vivo (183). Expression of an activated form of the TGF-β type I
receptors ActRIB/ALK-4 or ALK-5 can also induce EMT in mouse mammary
tissue(184) while dominant negative forms of ALK-5 can inhibit EMT (185).
Binding of TGF-β induced signaling through both Smad2 and Smad3 by cterminal phosphorylation by TGFβRI. Smad3 and Smad4 form trimmers with Smad4
before translocating to the nucleus where they regulate transcription. Smad signaling
directly regulates 3 families of transcription factors related to EMT: Snail family, ZEB
family and the basic helix-loop-helix (bHLH) family (e.g. Twist) (186).
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Chapter 6: General Discussion

151

The central hypothesis of this dissertation is that Inflammatory breast cancer is
distinguished

from

other

non-inflammatory

breast

cancers

by

unique

immunological characteristics that contribute to the rapid progression of the
disease. I have presented data on inflammatory soluble factor from blood, hematology
profile and functional abilities of peripheral blood T and dendritic cells from
inflammatory breast cancer patients.

The number of IBC patients in this study is

unprecedented and could not have been accrued at any other institution. While there are
a few clear differences in the average expression of certain factors, notably an increase of
TGF-β in the serum and a possible decrease in serum CRP, the presence of highly
inflammatory Tc17 cells and the relative increase of inflammatory cells in MIBC
compared to MBC, this work has shown that there is not a clear immune signature that
distinguishes IBC from non-IBC. However, the responses of IBC cells to immunemediated inflammation show that inflammation can alter the aggressive tendencies of
disease by invoking an epithelial to mesenchymal transition that is associated with
increased invasion and migration. This induction of EMT by immune inflammatory
factors is not unique to IBC as a similar response was seen in cell lines representing an
array of breast cancer subtypes. Surprisingly, unique in IBC this EMT was only partial,
with an unconventional upregulation of E-cadherin that is a hallmark of IBC.
This work fails to provide strong evidence in support of the central hypothesis
that there is a unique IBC signature. While this work comes close to proving the
hypothesis wrong, the factors studied were expertly selected and not comprehensive;
therefore we cannot say that there is not a unique signature. The negative cannot be
proven as there are almost always new factors that can be considered. As life as we know
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it is mostly defined by genetics, whole genome sequencing would seem to capture most
of the possible states as the human genome is finite, at least technically (all combinations
of base pairs without considering insertions or deletions is nearly infinite at 43x10^9 = 9.6 x
101806179973 – that’s a nine followed by over 4 billion zeros). Yet, even this does not
account for interactions with the environment.

This merely serves to suggest that a

comprehensive screen would be nearly impossible. Never the less, the data presented
here do not provide a clear unique signature for inflammatory breast cancer.
The lack of an IBC-specific profile is consistent with previously described work
that approached inflammatory breast cancer from tumor genetics. Gene expression and
hybridization data using microdissected tumors from the Inflammatory Breast Cancer
Consortium others has failed to provide a consistent gene signature within the tumor
(170).

Furthermore, deep sequencing suggests that common driver mutations, while

present, are individually very rare, further suggesting that no single pathway has yet
provided a clear target for research and therapy.
In general, the median levels of soluble inflammatory mediators were lower in
IBC than in LABC. This was surprising finding as we had expected to see higher levels
of inflammation in IBC. However, it is consistent with the observed high levels of the
anti-inflammatory agent TGF-β1.
TGF-β1 is highly ubiquitous and pleiotropic. In terms of cancer progression, its
actions can both inhibit primary tumor growth and promote metastasis by inducing EMT.
Here we show that higher levels are associated with IBC. As all the patients in this study
had advanced disease, it is possible that the tumor has progressed past a point where the
inhibitor growth effects of TGF-β1 would be most apparent.
Furthermore, we observed lower levels of IL-8 in IBC than in non-IBC. Again,
considering that IBC cell lines produce high levels of IL-8, this was not expected. Of
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course, IL-8 is produced by many cell types and local production of soluble factors can
be greatly diluted in circulation.
These observations of soluble factors suggest that modulation of
inflammation may be related to disease progression in IBC. The idea that immune cells
promote tumor growth is not new. Virchow first proposed the connection between
inflammation and cancer in 1836 (review (187)). Dvorak’s 1986 statement that cancer is
“a wound that does not heal” (188) is almost accepted as gospel. Cancer, he argues,
induces changes in the stroma similar to wound repair with changes in the extracellular
matrix and increased production and secretion of growth factors.
Studying the tumor microenvironment is tricky in inflammatory breast cancer. In
primary tumor samples, the amount of untreated tissue obtained from core biopsies is
minuscule at best and even with ultrasound guidance often return minimal tumor. Since
the majority of patients are treated with neoadjunantneoadjuvant therapy, the larger
samples obtained at surgery have been heavily treated. There is currently no mouse
model for inflammatory breast cancer as the molecular driver is still undefined. In vivo
studies are limited to xenografts of human derived cell lines. Therefore, we are limited to
describing the samples that are available and contriving co-culture experiments as we
have done in Chapter 5.

In Chapters 2-5 we have described immune

paramatersparameters from blood of IBC patients. Blood represents an ideal source of
minimally invasive tissue that can be samples longitudinally to observe changes over
time. While the work described here is limited to baseline samples, it lays a foundation
for future studies that will observe changes.
We observed normal levels of T cells in IBC patients but reduced levels in
metastatic breast cancer, both with and without inflammatory features. A CD4 T-cell
count of 200 or less cells/µL is severely immune deficient (this meets the definition of
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acquired immune deficiency symdromesyndrome – AIDS) and often requires
prophylactic treatment to prevent pneumocystis pneumonia and mycobacterium avium
complex. We observed 6 patients with CD4 T-cell counts below 200 (3 MIBC and 3
MBC, all previously treated with systemic therapy) and an additional 31 patients below
the “normal” limit of 500 (20 MIBC, 6 MBC, 3 IBC and 1 LABC) only 8 of whom where
treatment naïve. This suggests that while treated patients maybe immune compromised,
pre-treatementtreatment patients have a large number T cells that might be capable of
inducing an immune response.
Therefore, we tested the ability of T cells to respond to antigen in Chapterchapter
4. As shown in Figure 4.1D on page 98, both IBC and MIBC patients have CD4+ T cells
in numbers comparable to HD that are able to synthesize cytokines. This suggests a
highly intriguing possibility for an immune therapy approach. It is noteworthy that the
percentage of cells responding with cytotoxic, TH1 related cytokines are suppressed in
MIBC (but not IBC). This suggests that an immune-based approach might be more
feasible in stage-III rather than stage IV disease. In liquid tumors, it has been observed
that vaccination strategies are most successful against minimal residual disease.

If

similar principles are involved in breast cancer, it might be best to harvest T cells from
patients prior to therapy, expand them in vitro and return activated cells to the patient
following systemic therapy and surgical de-bulking. As we also observed slight defects
in dendritic cell number and ability in IBC patients (Figure 4.2 on page 105), the in vitro
stimulation may be a good option of eliciting an anti-tumor immune response.
In dendritic cell responses, IBC had an increase in pDC synthesized TNF-α and
mDC synthesized IL-10.

pDC activity tends to promote innate immunity through

recruitment and activation of macrophages with interferons. In contrast, mDC are more
related to adaptive immunity, however the observed increases in IL-10 synthesis would
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suggest that a cytotoxic immune response would be inhibited. Furthermore, LABC had
significantly higher expression levels of costimulatory and activating cell surface proteins
CD80, CD86 and CD40 than IBC. Together theses suggest that IBC has a defect in the
ability of DC to polarize T-cells towards an anti-tumor TH1 response.
Immune Induction of EMT
We have shown that TNF-α, TGF-β and IL-6 can contribute to the aggressiveness
of IBC by enhancing EMT. TGF-β can be hard to target clinically because of its ubiquity
and pleiotropic effects (ie., this stuff is everywhere and does everything).

We are

proposing here that immune derived TGF-β contributes significantly to the induction of
EMT within the tumor microenvironment. The Morgan Welch Inflammatory Breast
Cancer Research Program and Clinic at MD Anderson has recently proposed to test BP100.1.01 (liposomal antisense Grb-2) in IBC patients since Grb-2 is involved in the
signaling cascade initiated by EGFR signaling. However, Grb-2 is also involved in T cell
receptor (TCR) signaling (189). As such, administration of this drug should decrease T
cell responsiveness. Hui Gao showed such an effect following treatment of CML patients
with imatinib mesylate while designed to inhibit BCR-ABL tyrosine kinase signaling,
also inhibits Lck signaling at the top of the T-cell receptor signaling cascade (167).
Similarly, if the anti-Grb2 drug does reduce antigen specific immune responses, activated
TReg cells might produce less TGF-β. It would be easy to test polyclonal T-cell responses
to this drug using the methods presented in this thesis.

Additionally, new TGF-β

antibodies such as clone 9016 from R&D (190) not available at the initiation of this study
may allow for the direct quantification of TGF-β production by T-cells. Simultaneously,
EMT can be measured in circulating tumor cells (154).

Following from the data

presented here, we would expect that after initiation of tBP-100.1.001, there would be a
blunted T-cell cytokine response including decreased TGF-β synthesis that would
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correlate with decreased EMT. Inhibiting the TReg response would also have the benefit
of increasing NK activity within the tumor microenvironment.
Inhibiting TGF-β production by T-cells is a dangerous proposition however.
While this might decrease TReg activity, it will also decrease the TH1 response. We have
shown in Chapter 4 that a strong T-cell cytokine response is related to increased survival.
The EMT data shown in Figure 5.10 on page 140 suggests that IL-6 might be a
good target for preventing the maintenance of EMT. The spiking data shows that adding
IL-6 alone to unconditioned media had little effect on the induction of EMT at 48 hours.
However, depleting IL-6 from the conditioned media greatly reduced the EMT induction.
This suggests that an anti-IL-6 therapy would not be able to reduce induction of EMT,
but it might prevent EMT cells from persisting for extended periods of times. Further
study would be required to determine the appropriate time frame. If on the one hand,
EMT-induced cells are able to extravasate from the primary tumor, but blocking IL-6
reduced the EMT phenotype before they circulating tumor cells reach the metastatic site,
an anti-IL-6 therapy might prevent metastasis by preventpreventing the tumor cellcells
from invading new tissue. However, if the time period is longer, blocking IL-6 might be
help the tumor cells undergo MET (mesenchymal to epithelial transition) or reverse EMT
at a new metastatic site, allowing the cells to take up residence. In this case, the anti-IL-6
therapy would induce metastasis. Further experiments with the real-time cell analysis
might help tease this apart, but only an in vivo model can really test this effect.
Several anti-IL-6 drugs are currently in clinical trials. It is possible to target
either the soluble IL-6 ligand (such as siltuximab), the soluble IL-6 receptor required for
IL-6 signaling in most non-hematopoietic cells (such as anti-IL-6 receptor antibody
tocilizumab) (191), the GP130 subunit of the IL-6 receptor (192), or Jak2-Stat3 signaling
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(193).

Interestingly, metformin targets Stat3 in TNBC tumors, possibly offering

generally well -established therapy.
Alternatively, inflammation in general can be targeted such as through the widely
discredited Cox-2 enzyme, the prostaglandin (EP) receptors, or C-reactive protein. As
the data we presented here suggest that a strong T-cell response is beneficial to patients, a
therapeutic approach that can alter the TH1/TH2 balance in favor of TH1 would seem
preferable to an approach that targets T cells non-discriminately. For example, dendritic
cells exposed to prostaglandins take on a type-2 polarized effector DC polarization and
induce TH2 polarization in T-cells by producing less IL-12 (194). This would suggest
that a Cox-2 inhibitor, might be beneficial, if toxicities can be overcome. Long chain
fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found
in nutraceuticals such as fish oil alter the cyclooxygenase metabolism by favoring the
production of PGE3 over PGE2 have proven anti-inflammatory and anti-proliferative
properties (195); however, they do not seem to alter the TH1/TH2 balance (196). This
would suggest that while treatment with EPA (fish oil) might be beneficial in controlling
tumor growth both directly and by reducing inflammatory factors, it might not be the
strongest candidate for an optimal immune response. Alternatively, inflammation in
general can be targeted such as through the widely discredited Cox-2 enzyme, the
prostaglandin (EP) receptors, or C-reactive protein.

As the data we presented here

suggest that a strong T-cell response is beneficial to patients, a therapeutic approach that
can alter the TH1/TH2 balance in favor of TH1 would seem preferable to an approach
that targets T cells non-discriminately.

For example, dendritic cells exposed to

prostaglandins take on a type-2 polarized effector DC polarization and induce TH2
polarization in T-cells by producing less IL-12 (194). This would suggest that a Cox-2
inhibitor, might be beneficial, if toxicities can be overcome. Long chain fatty acids such
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as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in nutraceuticals
such as fish oil alter the cyclooxygenase metabolism by favoring the production of PGE3
over PGE2 have proven anti-inflammatory and anti-proliferative properties (195);
however, they do not seem to alter the TH1/TH2 balance (196). This would suggest that
while treatment with EPA (fish oil) might be beneficial in controlling tumor growth both
directly and by reducing inflammatory factors, it might not be the strongest candidate for
an optimal immune response.
Alternatively, statins (or HMG-CoA reductase inhibitors), used to control blood
cholesterol levels have a strong anti-inflammatory effect as well (197). As these drugs
are generally well tolerated and likely quite beneficial as IBC patients tend to be obese,
statins offer a highly intriguing possible therapy.
In total, the data here suggest multiple possible therapeutic targets, however, we
lack a well-validated system for testing.
Proposed Animal Model
Clearly one of the major limitations of this work is the lack of in vivo data. We
have presented ex vivo data to show that immune cells in IBC are competent. We have
performed co-culture experiments of normal donor leukocytes with IBC cell lines. But
we do not know how these cells interact in the microenvironment. Presently, all IBC in
vivo models are xenografts of human-derived cell lines in immune compromised mice.
Developing a true in vivo model would require an understanding of the molecular basis
for IBC that currently does not exist.
One alternative that might yield some answers would be to induce tolerance to the
human cell in the mouse model. Some researchers have been able to transplant human
cell lines into mice with fully intact immune systems by overexpressing CCL21 in the
tumor cell. CCl21 recruits T cells to the tumor, but the majority of the cells recruited are
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TReg that lead to immune tolerance. In a melanoma model, tumors with low CCL21
showed antigen specific immunity and whereas tumors expressing high levels of CCL21
induced tumor tolerance with high levels of TGF-β and even protect distant, non-CCL21
expressing tumor co-implanted at the same time, even in the non-syngeneic cell lines
(198). Such a model might allow transplanting human IBC cell lines into immune
competent mice. However, would this truly model IBC? Probably not! For one, it
seems like the microenvironment plays a critical role, if the host is left genetically
unperturbed, we might miss a critical part of the disease. The data we presented here
suggest that a normal immune response is capable of inducing aggressive features in
breast cells, including the non-tumorigenic cell line MCF-10a. So the question is: what
dysregulation in immune activation can lead to this?
As an alternative to a genetically engineered model, combinations of in vitro
stimulation and xenograft implantation may also get closer to providing an in vitro model
for the interactions of immune cells and IBC tumors. For example, we have shown here
that phenotypic changes are induced in IBC cells when exposed to soluble factors from
immune cells. These EMT-induced cells can be transplanted into immune compromised
mice once exposed to conditioning factors in vitro (see Illustration 6.1). As IBC cell
lines are tumorigenic and metastatic, the end point would have to be the rate and number
of metastases formed. These results would require a sufficiently powered experiment, as
the results are unlikely to yield a clear, unambiguous answer. To help establish the
timing of metastasis (particularly since the effects of the immune induced EMT are likely
transitory), the primary tumor can be removed once it is established.
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Illustration 6.1
Proposed in vivo model. Since no mouse model of IBC exists, tumor-immune
interactions would have to be modeled in vitro and then transferred to a xenograft setting.
To test weather immune-induced EMT contributes to metastasis, we propose exposing
IBC cell lines to immune conditioned media in vitro prior to transplantation into the
cleared mammary fat pads of immune compromised mice. The number and rate of
metastases would be used as an endpoint.
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Perhaps even more fundamental than a lack of an in vivo model, we currently
have a very poor understanding of what leukocytes are involved within IBC tumors. This
limitation is due, in part, to the very scarce pre-treatment samples available. Currently, a
core biopsy is routinely taken prior to surgery. We have recently initiated a protocol in
collaboration with Dr. Radvanyi to retrieve tumor-infiltrating lymphocytes from these
samples to better characterize immune states as they are within the tumor. We hope this
will validate the findings we saw in blood and in our in vitro studies.
In summary, inflammatory breast cancer is a complex and highly aggressive
disease that has not yet been defined on the molecular level by examining the tumor
alone. We proposed that tumor host interactions, specifically between immune cells and
tumor cells could help explain some of the unique etiology of IBC. We failed to define a
clear IBC signature within soluble factors from the blood or from circulating
hematopoietic cells. However we noted differences between IBC and non-IBC that
suggest immune regulation might play a role in the disease. We showed that like most
breast cancers, IBC could be induced to a more aggressive state by soluble immune
factors including IL-6, TNF-α and TGF-β as demonstrated by the induction of EMTrelated factors and migration in SUM149 cells. Strikingly, we found that one of the most
perplexing hallmarks of IBC, the persistence of E-cadherin expression in a highly
metastatic disease, can be mediated by these immune factors. Blocking these interactions
specifically with targeted therapy or by targeting inflammation in general might offer a
beneficial therapeutic approach.
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Chapter 7: Methods
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PATIENT RECRUITMENT
All patient studies were completed at The University of Texas MD Anderson
Cancer Center. For cellular immune studies, patients were recruited to lab protocol
Lab08-0199 “ Reactivation of Epstein - Barr virus in Patients with Breast Cancer.” The
serum profiling studies also included patients recruited under the Inflammatory Breast
Cancer Registry, 2006-1072.

All patients provided written informed consent in

compliance with the World Medical Association Declaration of Helsinki. Eligibilty
criteria for Lab08-0199 included women with advanced breast cancer starting a new line
of therapy. Initial target enrollment called for enrollment of 30 patients from each of the
following 4 diagnoses: locally advanced breast cancer (LABC), inflammatory breast
cancer (IBC), metastatic breast cancer (MBC) with IBC, and metastatic breast cancer
with inflammatory features (MIBC). Enrollment of patients with IBC was later extended
to 200 patients. The registry protocol contains two cohorts of patients diagnosed with
IBC. Cohort I is restricted to newly diagnosed patients. By design, patients should be
untreated at the time of sample collection, however discrepancies in the timing of
enrollment, treatment initiation and sample collection account for several samples
collected after treatment. Cohort II includes patients with a diagnosis of IBC that have
already initiated treatment.

These are usually patients that were diagnosed in the

community and referred to MD Anderson.
Clinical correlates were collected by chart review from the MD Anderson
electronic medical record system ClinicStation. Pathology results and lab tests were
entered into the database by the author or other lab members, but tumor staging and
survival times were all evaluated and entered into the database by clinicians with a
medical doctorate.
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Clinical staging was based on AJCC criteria (9). The tumor markers estrogen
receptor (ER) and progesterone receptor (PR) were evaluated by immunohistochemistry
(IHC) of fine needle aspirates or surgical excisions of the primary tumor, as reported by a
board certified pathologist. Tumors were scored as positive if 5% of the cells were
positive for the marker. Her2 was evaluated by immunohistochemistry and fluorescent
in-situ hybridization (FISH) when available. Tumors were considered Her2 positive if
they were scored 3+ on IHC or had a Her2/CEP 17 ratio >2 by FISH. Amplification by
FISH was considered the gold standard such that if there were discrepant scores by FISH
and IHC, the FISH categorization was used for classification (ie., an IHC 3+, FISHtumor was classified as Her2 negative). The proliferation marker Ki67, which is a good
surrogate marker for discriminating between Luminal A and Luminal B intrinsic subtypes
is rarely requested at MD Anderson and was not included in the analysis.

SAMPLE COLLECTION
All samples were collected at University of Texas MD Anderson Cancer Center
and processed in the lab of James M. Reuben, PhD. Peripheral blood samples were
collected by venipuncture into evacuated tubes. Samples collected under Lab08-0199
included a single 10 mL red-top tube containing no anti-coagulants for serum analyses
and six 10 mL green-top tubes with heparin anti-coagulant for cellular analyses. Samples
collected under 2006-1072 included one 10 mL red-top serum tube and two 10 mL purple
top tubes with EDTA anti-coagulant. Lab08-0199 samples were processed within 24hours of drawing.
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FREEZE SERUM AND PLASMA
Plasma was collected from green heparinzed tubes and serum from red-top tubes
without anti-coagulant.

Tubes were centrifuged for 20 minutes at 1200 g. Serum was

harvested from above the clot without disturbing the pellet and plasma was harvested
above the buffy coat leaving at least a few millimeters of plasma to prevent collecting
cells. Samples were aliquoted into three 1-mL tubes with silicon O-rings to minimize
loss to evaporation. Aliquots were frozen temporarily at -20˚C until the storage box is
filled and transferred to -80˚C for long-term storage.
FREEZE PBMC
Anti-coagulated blood (heparin for most studies) was diluted with at least an
equal volume of phosphate buffered saline (PBS) up to a total volume of 30-35 mL. The
diluted blood was slowly layered over room temperature Ficoll-Paque Plus (GE
Healthcare Life Sciences, Pittsburg, PA). This solution consists of a mixture of the
hydrophilic polysaccharide Ficoll PM400 and sodium diatrizoate.

This produces a

solution with a density of 1.078 g/mL, intermediate to the density of a red blood cell
(1.096 g/mL) or polymorphonuclear leukocyte (1.06 – 1.10) and the density of a
mononuclear leukocyte. After a 30-minute centrifugation at 400g with the break off,
peripheral blood mononuclear cells (PBMC) were harvested from the interface between
the Ficoll and the diluted plasma. The centrifuge break must remain off to prevent
vibrations from disturbing the phase interfaces. PBMC consist of lymphocytes and
monocytes although typically had a small erythrocytic and granulocytic contamination
was present, particularly in patient samples. PBMC were washed two times by adding
PBS to the cells and followed by a 10-minute centrifugation at 300g at room temperature
to pellet the cells. To freeze the cells, the cell pellet was resuspended in 1-mL of freezing
buffer consisting of 10% dimethyl solfoxide (DMSO) and 90% heat inactivated, certified
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low endotoxin fetal bovine serum

(FBS, Life Technologies, Carlsbad, CA).

As

endotoxin activates PBMC through the TLR-4, it is critical that only high-quality FBS is
used. Cell aliquots were positioned in a “Mr. Frosty” cryogenic freezing container and
placed into a -80˚C freezer overnight. The isopropanol in the freezer container maintains
a 1˚C/min freezing rate which prevents cell rupture. After equilibrating to the -80˚C
temperature, cell aliquots were transferred to a liquid nitrogen freezer for long-term
preservation.
THAWING CELLS
To thaw cryopreserved cells, an aliquot was removed from the liquid nitrogen
tank and rapidly thawed by placing the frozen tube in a 37˚C water bath with gentle
agitation for approximately 1 minute. Once the cells had thawed, the mixture was
transferred to a polypropylene conical tube.

Complete media consisting of RPMI

supplemented with10% FBS and antibiotic was added drop-wise to restore physiologic
osmolality. The cells were washed twice with complete media by centrifugation at 400g
for 10 minutes, counted by trypan blue exclusion assay using a hemocytometer with an
improved Neubauer grid and resuspended in complete media at 1 x 106 cells per mL.
CELL CULTURE
All cells were cultured in tissue-culture treated plastic vessels and incubated in a
5% CO2 atmosphere at 37˚C. PBMC were incubated in RPMI 1640 (Corning, Manassas,
VA)

supplemented

with

10%

low

endotoxin

certified

FBS

and

antibiotic

(penicillin/streptomycin) or antibiotic/antimycotic (penicillin/streptomycin/amphotericin
B; Life Technologies, Carlsbad, CA).
IBC cell lines used in this study include: SUM149PT, SUM190PT, KPL-4, and
IBC-3. SUM149PT cells, SUM190PT and the non-IBC cell line SUM159PT (abbreviated
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to SUM149, SUM190, and SUM159PT respectively throughout this dissertation) were
obtained courtesy of Dr. Stephen Ethier (Kramanos Institute, MI, USA) and are
commercially available (Asterand, Detroit, MI). Cells were cultured in Ham's F-12
media supplemented with 10% FBS, 1 µg/mL hydrocortisone, 5 µg/mL insulin and
antibiotic-antimycotic (referred to as “IBC media”).
IBC-3 cells were provided courtesy of Dr. Wendy A. Woodward (36) (MD
Anderson Cancer Center, Houston, TX) and cultured in Ham's F12 with 10% FBS and 5
µg/mL Insulin/L with 100 µg/L Hydrocortisone and antibiotic-antimycotic. KPL4 was
kindly provided by Dr. Junichi Kurebayashi (Kawasaki Medical School, Japan) and was
maintained in DMEM/F12 medium supplemented with 10% FBS and antibioticantimycotic.
MDA-MB 231 breast cancer cells were obtained from the American Type Culture
Collection (Manassas, VA) and grown in DMEM/F12 50/50 culture media supplemented
with 10% Gibco® certified FBS (Life Technilogies™, Grand Island, NY).
The normal mammary epithelial cell line MCF-10a was cultured in DMEM/F12
supplemented with 5% horse serum (not FBS), 20 ng/mL EGF, 100 ng/mL cholera toxin
0.01 mg/mL insulin, and 500 ng/mL hydrocortisone. Cholera toxin increases intracellular
levels of cAMP and increases growth in epithelial cells and helps the growth of normal
human mammary epithelial cells but has heterogeneous effects on tumor cell growth
which typically have elevated cAMP (199).
Cell line culture conditions are summarized in Table 7.1 Cell Lines.
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Table 7.1 Cell Lines
Breast cancer cell line culture conditions are listed. SUM149, SUM190, KPL4 and IBC-3 are the IBC model cell lines.
SUM149 is TNBC while the other IBC cell lines are Her2+. Additionally, SKBR3 was used as a Her2+ cell line. MDA-MB231 was used as the prototypical mesenchymal breast cancer cell line. SUM159 was used as a claudin-low cell line. MCF-7
and T47D were used as luminal, HR+ cell lines. MDA-453 was used as a TNBC, androgen receptor positive cell line. MCF10a was used as a normal, non-tumorigenic cell line.
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Cell Line

Source

Culture Media

Type

Type

ER

PR

Her2

EGFR

IBC-3

Wendy Woodward (MD Anderson)

Ham's F12 5% FBS HI

IBC

Luminal B

N

N

P

N

SUM149PT

Stephen Ethier (Asterand, Detroit, MI)

Ham's F12 5% FBS HI

IBC, TNBC

Basal-like

N

N

N

P

SUM159PT

Stephen Ethier (Asterand, Detroit, MI)

Ham's F12 5% FBS HI

TNBC

Claudin-low

N

N

P

P

SUM190PT

Stephen Ethier (Asterand, Detroit, MI)
Dr. Junichi Kurebayashi
(Kawasaki Medical School, Japan)

Ham's F12 5% FBS HI

IBC

Luminal B

N

N

P

P

DMEM/F12 10% FBS

IBC

Luminal B

N

N

P

P

DMEM/F12 , Cholera Toxin

non-tumorigenic

Basal-like

N

N

N

P

KPL-4
MCF-10a

ATCC

MCF-7

ATCC

DMEM/F12 10% FBS

epithelial

Luminal A

P

P

N

N

MDA-MB-231

ATCC

DMEM/F12 10% FBS

mesenchymal

Claudin-low

N

N

P

N

MDA-MB-453

ATCC

DMEM/F12 10% FBS

androgen+

Unclass.

N

N

P

N

SK-BR-3

ATCC

DMEM/F12 10% FBS

Her2+

Her2

N

N

P

P

T47D

ATCC

RPMI 10% FBS

epithelial

Luminal A

P

P

P

P

5% Horse Serum, EHI
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HI – Hydrocortisone 100µg/mL, Insulin 5µg/mL
EHI – EGF 20ng/mL, Hydrocortisone 100µg/mL, Insulin 5µg/mL
FBS – Fetal Bovine Serum

CM PREPARATION
Immune conditioned media as described in Chapter 5 was prepared from healthy
donor PBMC.

Fresh peripheral blood was collected from healthy volunteers by

venipuncture into heparinized Vacutainer collection tubes (BD, Frankiln Lakes, NJ). The
mononuclear cell fraction (PBMC) was collected by density gradient centrifugation over
Ficoll-Paque media (GE Healthcare Bio-Sciences Corp., Piscataway, NJ). PBMC were
cultured at an initial density of 1 x 106 cell per mL in RPMI 1640 supplemented with
10% Gibco® certified fetal bovine serum (FBS, Life Technilogies™, Grand Island, NY)
plus antibiotic-antimycotic. To activate the PBMC, cells were stimulated with platebound anti-CD3 (coated at 8 µg/mL) plus soluble anti-CD28 antibodies (200), 10 µg/mL
lipopolysaccharide (LPS), or left unstimulated.

Following 48 hours of culture,

conditioned media were collected and centrifuged at 400 g to pellet cells and debris. The
supernatant was clarified with a 0.22 µm pore filter and frozen in multiple aliquots at 80˚C. Prior to culturing with breast cancer cell lines, the conditioned media was diluted
1:4 with IBC media (note – migration assays used serum-free IBC media). For cell lines
other than SUM149, the appropriate media was used as noted in the “Cell Culture”
section above. TGF-β1 (R&D Systems, Minneapolis, MN) was used at 2 ng/mL in the
appropriate media as a positive control for EMT induction.

FLOW CYTOMETRY BASICS
Multi-Color Flow Cytometry
Most flow cytometry acquisitions were performed on a BD LSR II (Becton,
Dickinson and Company, San Jose, CA) equipped with two lasers and 6-color, 8172

parameter capability.

The red laser is a 635-nm 20 mW HeNe laser supporting 2

fluorescent channels in a trigon filter set. The blue laser is a 488 nm 20 mW Coherent
Saphire air-cooled argon laser providing the side-scatter channel (SSC) and 4 fluorescent
channels plus the side scatter channel arranged in an octagon format. Data was acquired
in BD FACS Diva version 6.1.1. Data was analyzed in FlowJo data analysis software for
flow cytometry (TreeStar, Inc, Ashland, OR) on a PowerMac computer running Mac OS
X. Both the software and the computer were upgraded over the course of the studies.
FlowJo versions included release 8.7.1 through 9.6.1. All data was reanalyzed and
confirmed after the transition from version 8 to 9.
4-Color ICC
In addition some 4-color experiments, most notably the intracellular cytokine
syntheses from the TCR-stimulated PBMC in the Lab08-0199 protocol, were acquired
using a BD FACS Calibur flow cytometer equipped with a 488 nm air-cooled blue argon
laser supporting 3 fluorescent channels plus forward channel light scatter (FSC) and SSC
and a 635 nm red diode laser for a the single APC channel. The Calibur flow cytometer
is driven by a PowerMac G4 running OS 9.1.0 and CellQuest 3.3. This 4-color data was
analyzed in Cell Quest Pro version 6 on a PowerMac running Mac OS X. The host
analysis computer was upgraded over the course of the studies. The current machine is
configured with a 2.8 GHz quad-core Intel xenon processor with 16 GB of RAM, a 1 TB
system hard drive, a 1.5 TB drive for data, and a 2 TB back-up drive that runs hourly
back-ups via Apple Time Machine.
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FRESH PHENOTYPES
Fresh whole blood from collected in hepainized collection tubes was processed
within 24 hours of collection.

Aliquots of 200µL were reacted with fluorophore-

conjugated monoclonal antibodies in panels including up to 6 colors (BD Bioscience, San
Jose, CA). Reactions were incubated in the dark at room temperature for 30 minutes.
Subsequently, the red blood cells were lysed with BD FACS/Lyse for 10 minutes at room
temperature and the washed twice by centrifugation using a Helmer UltraCW cell washer
(Helmer Scientific, Noblesville, IN) in PBS. Samples were resuspended in PBS prior to
acquisition. Cytometric data was acquired using the BD LSR II. Invitrogen CountBright
beads were added to the dendritic cell tube to enumerate absolute counts of dendritic
cells.
DC FUNCTIONAL TESTS
Fresh whole blood from collected in heparinized collection tubes was processed
within 4 hours of collection, as pDC in particular can be difficult to find in older samples.
Aliquots 4 aliquots of 1mL were reacted placed in polypropylene 15 mL conical tubes.
Two tubes were used for overnight stimulations for upregualtion of co-stimulatory
molecules and activation markers with either TLR7 and TLR8 agonists TLR075 and
TLR097 (Invivogen, San Diego, CA) or left unstimulated. CL075 activates TLR8 and
TLR7 to a lesser extent. CL097 is a water-soluble derivative of the imidazoquinoline
compound R848 and stimulates TLR 7 and 8. The other two tubes were similarly reacted
with the TLR agonists or left unstimulated for 4 hours for quantification of cytokine
synthesis, however, if the samples were received after noon, the samples were left at
room temperature and stimulated the following morning. Brefeldin A was added the final
3 hours to block Golgi transport and maintain de novo synthesized cytokines in the cell.
Following stimulation, samples were fixed and red blood cells were lysed with 10 mL of
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BD FACS/Lyse and washed 2 times with PBS. Aliquots of 200 µL were reacted with
fluorophore-conjugated monoclonal antibodies in panels including up to 6 colors (BD
Bioscience, San Jose, CA). Reactions were incubated in the dark at room temperature for
30 minutes.

Subsequently, samples were washed twice by centrifugation in PBS.

Samples were resuspended in PBS prior to acquisition. Cytometric data was acquired
using the BD LSR II.

SERUM CYTOKINE ANALYSIS (LUMINEX)
Serum samples were collected as described above from MD Anderson protocols
Lab08-0199 and 2006-1072. Samples were analyzed in batch using Milliplex bead kits
(EMD Millipore Corporation, Billerica, MA) according to the manufacture protocol with
overnight incubations and an additional point added at the low end of the standard curve
and acquired using a Luminex LX100 (Luminex Corporation, Austin, TX) running
BioPlex control and analysis software Version 5.0, (BioRad, Hercules, CA).
T-CELL STIMULATION THROUGH T-CELL RECEPTOR (ANTI-CD3 STIMULATION)
To interrogate T-cell function, T-cells were activated polyclonally through the Tcell receptor. Anti-CD3 antibody immobilized to plastic can cross-link T-cell receptors
on T-cells establishing a localized cluster of receptors (supramolecular activation cluster
or SMAC) reminiscent of an immunological synapse. This facilitates phosphorylation of
immunoreceptor tyrosine-based activation motifs. Soluble anti-CD28 antibody is added
as a “signal 2” to mimic co-receptor binding. In these experiments, anti-CD3 antibody
(Beckman Coulter, clone UCHT1) was added to tissue-culture 6-well plates at 8 µg/mL
in 625 µL per well. The tyrosine residues on the antibody react with the benzene rings in
the polystyrene to facilitate binding at alkaline pH, but binding is sufficient in PBS at
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physiological pH with a 6-hour incubation at 37˚C and in a 5% CO2 humidified
atmosphere. Prior to freezing, the pre-coated plates were air-dried in a laminar flow hood
overnight. To stimulate T-cells, 50 µL of 150 µg/mL anti-CD28 antibody (BD340975,
clone L293) was added to a thawed plate pre-coated with anti-CD3 antibody. Five (5)
mL of PBMC were added to each well at 1-2x106 per mL in complete RPMI for a total of
5-10 x 106 PBMC per well.
For intracellular cytokine synthesis assays, cells were stimulated overnight at
37˚C in a 5% CO2 humidified atmosphere. Next, cells were removed by gentle scrapping
utilizing a 1-mL pipette tip. Cells were fixed for 10 minutes with BD FACS Lyse/Fix (a
solution that contains <1.5% formaldehyde and <5.0% diethyene gycol at working
concentrations).
For experiments utilizing conditioned media, cells were stimulated for 2 days at
1x106 cells/mL. After culture, media was aspirated and filtered with a 0.22 micron
syringe filter to excluded cellular factors and contaminants.

MRNA

Trizol / Chloroform Extraction
Following treatments, samples were frozen in 700 µL Qialzol lysis reagent
(Qiagen Germantown, MD) at -80˚C and processed in bulk. Total RNA was extracted
with chloroform and processed using the Qiagen miRNeasy Mini Kit on a Qiacube
automation unit according to manufacture protocol (Qiagen, Valencia, CA) to standardize
the RNA isolation procedure. All RNA preparation and handling steps took place in a
laminar flow hood, under RNase-free conditions. RNA concentration was determined
using a NanoDrop 2000 spectrophotometer (ThermoScientific, Wilmington, DE).
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Typically 10 µg of RNA was recovered (range 0.1µg – 62µg). cDNA was synthesized by
reverse transcription of 1µg of RNA and random primers using the high-capacity cDNA
reverse transcription kit (Life Technologies, Foster City, CA).

2-Step RT-PCR
GENE EXPRESSION ANALYSIS BY QUANTITATIVE POLYMERASE CHAIN REACTION
Gene expression was quantified with real-time reverse transcription-polymerase
chain reaction (RT-PCR) using TaqMan® hydrolysis probe gene expression assays (Life
Technologies) using a 7900HT Fast Real-Time PCR System (Life Technologies),
following the manufacturer's instructions. Universal thermo cycling conditions were
used. Assay setup was performed on a Qiagility liquid handler (Qiagen) to standardize
pipetting. The amplification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used to normalize gene expression levels, and the relative expression of each gene
was calculated using the equation 2-∆Ct, where ∆Ct = mean Ctgene – CtGAPDH, or 2-∆∆Ct,
where ∆∆Ct = (Ctgene – CtGAPDH) conditioned media – (Ctgene – CtGAPDH) control media.
TaqMan® assays were purchased from ABI: GAPDH: Hs02758991_g1, CDH1 (Ecadherin):

Hs01023894_m1,

CDH2

(N-cadherin):

HS00983056_m1,

EPCAM:

Hs00158980_m1, FN1 (fibronectin): Hs00365052_m1, KRT19: Hs00761767_s1, SNAI1
(SNAIL1):

Hs00195591_m1,

SNAI2

(Slug):

HS00161904_m1,

TGM2

(TG2):

Hs00190278_m1, TWIST1: Hs00361186_m1, VIM (Vimentin): Hs00185584_m1, and
ZEB1: Hs00232783_m1. Data were analyzed with the use of the 7900 Fast System SDS
software, Version 2.4 Standalone. All experiments were performed in triplicate.
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Fluidigm RT-PCR
To analyze the EMT profile of multiple cell-lines, a high throughput PCR
technology was employed.

Multiplex qRT-PCR was performed using Fluidgm®

integrated fluidic circuits. This system consists of microfluidic chips that mix each
sample with each assay in a 1:1 relationship and an qRT-PCR thermocycler and data
acquisition platform know as the BioMark HD. The chips utilized for these experiments
were 48.48 Dynamic ArrayTM chips containing 48 assay wells and 48 sample wells. The
microfluidics distribute each 5µL sample mixture containing cDNA and mastermix
between 48 TaqMan® hydrolysis probe assays. This produces an array of 2,304 wells
with a 35 nl reaction volume. This automated system increases consistency and saves
both hands-on pipetting time, sample volume, and reagent volume. However, to ensure
equal distribution into each of the very small 35nl wells, a pre-amplification step must be
performed prior to arraying the samples. Without the pre-amplification, rare cDNA will
be subjected to a binomial distribution amongst the wells, where some wells will start
with a single copy of the cDNA and others will have 0 or 2 (note – typically the single
cDNA will reach threshold at about cycle 30, thus any data with a CT value around 30 or
higher is of little analytic value with a small number of replicate wells).
Prior to quantitative real-time PCR (qRT-PCR) analysis, 2.5 µL of cDNA was
subjected to 14 cycles of multiplex sequence specific amplification using TaqMan®
PreAmp Master Mix and TaqMan® Gene Expression Assays. The product was diluted
1:5 in TE. The cycling program was 95˚C for 10 minutes followed by 14 cycles of 95˚C
for 15 seconds and 60˚C for 4 minutes. qRT-PCR was performed using the Fluidigm®
48.48 dynamic array integrated fluidic circuit and BioMark HD® analysis system using
the GE 48x48 Standard v1 thermal protocol. Samples were run in duplicate. TaqMan®
hydrolysis probe assays used for pre-amp and qRT-PCR. Data were analyzed with the
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BioMark Real-Time PCR Analysis Software Version 2.0 (Fluidigm).

Expression

changes were calculated using the ∆Ct method using beta-2-microglobin as the
endogenous control. For each cell line, the media control was used as the normalizer.
CELL BOCK AND IHC
Cells from each of the cell lines were made into cell blocks for
immunohistochemical (IHC) staining. Control cells (MCF-7 and MDA-MB-231) were
grown in the appropriate media as noted above and SUM149 cells were exposed to CM
for 48 hours. Cells were harvested following trypisnization and washed twice in PBS.
5x105 cells were cytospun unto poly-lysine coated slides, air-dried for overnight and then
fixed in (%?) ethanol prior to Diff-Quick staining. Additionally, 2x107 cells for each cell
line were fixed in 10% formalin for 16 hours, pelleted by centrifugation and embedded in
paraffin, as previously described (201). Cell blocks were sectioned and used for IHC
staining.

MAMMOSPHERE
SUM149 cells cultured in monolayer were exposed to CM for 48 hours as above,
trypsonized, washed twice with PBS to remove serum and resuspended in serum-free
media containing FGF-b, and EGF “mammosphere media”, as previously described (161,
202) and cultured for 6 days prior to counting. Conditioned media was not added to the
mammosphere culture.
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XCELLIGENCE REAL-TIME CELL ANALYSIS

To test the changes in migratory and invasive capacity of SUM149 IBC cells, cell
migration was quantified with the xCelligence Real Time Cell Analyzer Cell Invasion
Migration (CIM)-plate 16 platform (Acea Biosciences, San Diego, CA) using FBS as a
chemoattractant for SUM149 cells. The CIM plate is essentially a Boyden chamber that
measures increasing impedance on the lower surface of the semi-permeable membrane as
cells migrate into the lower chamber. To ensure that chemoattractant factors in the CM
did not affect migration, 25% CM was placed in both the upper and lower chambers. The
CM was diluted with serum-free IBC media in the upper chamber while the lower
chamber used IBC media supplemented with 10% FBS. Serum free media in the lower
chamber was used as a negative migration control.

Cells were suspended in the

appropriate media and added to the upper chamber as per manufacture protocol.
Impedance was measured on the receiving surface in the lower chamber as a measure of
cell migration and normalized to a Cell Index with RTCA software version 1.2.0.0909
(Roche Applied Science Indianapolis, IN, under license from Acea Biosciences, Inc., San
Diego, CA).
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